United States

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

(Mark One)


☒			QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, ~~2021~~2022


☐			TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 000-23661

ROCKWELL MEDICAL, INC.

(Exact name of registrant as specified in its charter)


Delaware									38-3317208
(State or other jurisdiction of incorporation or organization)									(I.R.S. Employer Identification No.)
30142 S. Wixom Road, Wixom, Michigan									48393
(Address of principal executive offices)									(Zip Code)

(248) 960-9009

(Registrant’s telephone number, including area code)

(Former name, former address and former fiscal year,

if changed since last report)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ Yes ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☒

Securities registered pursuant to Section 12(b) of the Act:

Title of each class:

Trading Symbol

Name of each exchange on which registered:

Common Stock, par value $0.0001

RMTI

Nasdaq ~~Global~~Capital Market

The number of shares of common stock outstanding as of August ~~13, 2021~~12, 2022 was ~~93,888,881.~~10,675,193.

Rockwell Medical, Inc. and Subsidiaries

Index to Form 10-Q


			Page
Part I — Financial Information (unaudited)

Item 1 - Financial Statements

Condensed Consolidated Balance Sheets as of June 30 ~~2021~~, 2022 and December 31, ~~2020~~2021			3

Condensed Consolidated Statements of Operations for the Three and ~~Six~~S ix Months Ended ~~June~~J une 30 , 2022 and 2021 ~~and 2020~~			4

Condensed Consolidated Statements of Comprehensive Loss for the Three and ~~Six~~S ix Months Ended~~June~~J une 30 ~~2021~~, 2022 and ~~2020~~2021			5

Condensed Consolidated Statements of Changes in Stockholders’ Equity for the Three and ~~Six~~S ix Months Ended ~~June~~J une 30 , 2022 and 2021 ~~and 2020~~			6

Condensed Consolidated Statements of Cash Flows for the ~~Six~~S ix Months Ended ~~June~~J une 30 , 2022 and 2021 ~~and 2020~~			7

Notes to Condensed Consolidated Financial Statements			87

Item 2 - Management’s Discussion and Analysis of Financial Condition and Results of Operations			2722

Item 3 - Quantitative and Qualitative Disclosures about Market Risk			3626

Item 4 - Controls and Procedures			3626

Part II — Other Information

Item 1 - Legal Proceedings			3727

Item 1A - Risk Factors			3727

Item 2 - Unregistered Sales of Equity Securities and Use of Proceeds			28

Item 3 - Defaults Upon Senior Securities			28

Item 4 - Mine Safety Disclosures			28

Item 5 - Other Information			28

Item 6 - Exhibits			4429

Signatures			4530

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements

ROCKWELL MEDICAL, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(Dollars inIn Thousands)


		June 30, 2021		December 31, 2020			June 30, 2022		December 31, 2021
		(Unaudited)					(Unaudited)
ASSETS	ASSETS					ASSETS
Cash and Cash Equivalents	Cash and Cash Equivalents	$	32,378	$	48,682	Cash and Cash Equivalents	$	30,780	$	13,280
Investments Available-for-Sale	Investments Available-for-Sale	8,574		9,997		Investments Available-for-Sale	—		9,158
Accounts Receivable, net	Accounts Receivable, net	5,357		4,171		Accounts Receivable, net	8,090		5,913

Inventory, net	Inventory, net	4,677		3,913		Inventory, net	5,171		4,076
Prepaid and Other Current Assets	Prepaid and Other Current Assets	1,413		2,706		Prepaid and Other Current Assets	3,204		2,861
Total Current Assets	Total Current Assets	52,399		69,469		Total Current Assets	47,245		35,288
Property and Equipment, net	Property and Equipment, net	2,529		2,642		Property and Equipment, net	2,289		2,486
Inventory, Non-Current	Inventory, Non-Current	1,122		1,176		Inventory, Non-Current	1,481		1,523
Right of Use Assets, net	Right of Use Assets, net	6,085		2,911		Right of Use Assets, net	6,671		7,737

Goodwill	Goodwill	921		921		Goodwill	921		921
Other Non-Current Assets	Other Non-Current Assets	628		629		Other Non-Current Assets	509		619
Total Assets	Total Assets	$	63,684	$	77,748	Total Assets	$	59,116	$	48,574
LIABILITIES AND STOCKHOLDERS’ EQUITY	LIABILITIES AND STOCKHOLDERS’ EQUITY					LIABILITIES AND STOCKHOLDERS’ EQUITY
Accounts Payable	Accounts Payable	$	4,932	$	4,155	Accounts Payable	$	2,942	$	3,739
Accrued Liabilities	Accrued Liabilities	3,993		5,013		Accrued Liabilities	4,660		5,090

Lease Liability - Current	Lease Liability - Current	1,674		1,167		Lease Liability - Current	1,935		2,004
Deferred License Revenue - Current	Deferred License Revenue - Current	2,166		2,175		Deferred License Revenue - Current	2,169		2,171
Term Loan - Net of Issuance Costs	Term Loan - Net of Issuance Costs	21,133		0		Term Loan - Net of Issuance Costs	5,131		7,381
Insurance Financing Note Payable						Insurance Financing Note Payable	1,509		437
Customer Deposits						Customer Deposits	189		144

Customer Deposits		140		152
Other Current Liability - Related Party		0		131
Total Current Liabilities	Total Current Liabilities	34,038		12,793		Total Current Liabilities	18,535		20,966

Lease Liability - Long-Term	Lease Liability - Long-Term	4,506		1,821		Lease Liability - Long-Term	4,947		5,887
Term Loan, Net of Issuance Costs	Term Loan, Net of Issuance Costs	0		20,949		Term Loan, Net of Issuance Costs	10,370		13,186
Deferred License Revenue - Long-Term	Deferred License Revenue - Long-Term	6,937		8,015		Deferred License Revenue - Long-Term	5,105		5,986
Long Term Liability - Other						Long Term Liability - Other	14		14
Total Liabilities	Total Liabilities	45,481		43,578		Total Liabilities	38,971		46,039

Commitments and Contingencies (See Note 14)		0		0

Stockholders’ Equity:	Stockholders’ Equity:					Stockholders’ Equity:
Preferred Stock, $0.0001 par value, 2,000,000 shares authorized; 0 shares issued and outstanding at June 30, 2021 and December 31, 2020		0		0
Common Stock, $0.0001 par value; 170,000,000 shares authorized; 93,811,381 and 93,573,165 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively		9		9
Preferred Stock, $0.0001 par value, 2,000,000 shares authorized; 15,000 and nil shares issued and outstanding at June 30, 2022 and December 31, 2021						Preferred Stock, $0.0001 par value, 2,000,000 shares authorized; 15,000 and nil shares issued and outstanding at June 30, 2022 and December 31, 2021	—		—
Common Stock, $0.0001 par value; 170,000,000 shares authorized; 9,407,296 and 8,544,225 shares issued and outstanding at June 30, 2022 and December 31, 2021						Common Stock, $0.0001 par value; 170,000,000 shares authorized; 9,407,296 and 8,544,225 shares issued and outstanding at June 30, 2022 and December 31, 2021	1		1
Additional Paid-in Capital	Additional Paid-in Capital	371,700		371,510		Additional Paid-in Capital	402,304		372,562
Accumulated Deficit	Accumulated Deficit	(353,558)		(337,406)		Accumulated Deficit	(382,209)		(370,080)
Accumulated Other Comprehensive Income	Accumulated Other Comprehensive Income	52		57		Accumulated Other Comprehensive Income	49		52
Total Stockholders’ Equity	Total Stockholders’ Equity	18,203		34,170		Total Stockholders’ Equity	20,145		2,535
Total Liabilities and Stockholders’ Equity	Total Liabilities and Stockholders’ Equity	$	63,684	$	77,748	Total Liabilities and Stockholders’ Equity	$	59,116	$	48,574

The accompanying notes are an integral part of the condensed consolidated financial statements.

ROCKWELL MEDICAL, INC. AND SUBSIDIARIES

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(~~Dollars in~~In Thousands, Except Shares and Per Share Amounts)


		Three Months Ended June 30, 2021		Three Months Ended June 30, 2020		Six Months Ended June 30, 2021		Six Months Ended June 30, 2020			Three Months Ended June 30, 2022		Three Months Ended June 30, 2021		Six Months Ended June 30, 2022		Six Months Ended June 30, 2021

Net Sales	Net Sales	$	15,137	$	15,896	$	30,611	$	31,753	Net Sales	$	18,682	$	15,137	$	34,806	$	30,611
Cost of Sales	Cost of Sales	15,399		15,015		30,471		29,759		Cost of Sales	16,937		15,399		33,846		30,471
Gross Profit		(262)		881		140		1,994
Gross (Loss) Profit										Gross (Loss) Profit	1,745		(262)		960		140
Research and Product Development	Research and Product Development	2,416		1,616		4,224		3,438		Research and Product Development	926		2,416		2,494		4,224
Selling and Marketing	Selling and Marketing	1,468		1,997		3,319		4,069		Selling and Marketing	526		1,468		981		3,319
General and Administrative	General and Administrative	3,677		2,871		7,602		8,145		General and Administrative	4,775		3,677		8,592		7,602

Operating Loss	Operating Loss	(7,823)		(5,603)		(15,005)		(13,658)		Operating Loss	(4,482)		(7,823)		(11,107)		(15,005)

Other (Expense) Income	Other (Expense) Income									Other (Expense) Income
Realized (Loss) Gain on Investments		(1)		2		(1)		4
Warrant Modification Expense		0		(837)		0		(837)
Realized Gain on Investments										Realized Gain on Investments	—		(1)		4		(1)

Interest Expense	Interest Expense	(583)		(521)		(1,164)		(623)		Interest Expense	(485)		(583)		(1,021)		(1,164)
Interest Income	Interest Income	7		67		18		238		Interest Income	—		7		(4)		18
Total Other Expense	Total Other Expense	(577)		(1,289)		(1,147)		(1,218)		Total Other Expense	(485)		(577)		(1,021)		(1,147)

Net Loss	Net Loss	$	(8,400)	$	(6,892)	$	(16,152)	$	(14,876)	Net Loss	$	(4,967)	$	(8,400)	$	(12,128)	$	(16,152)

Basic and Diluted Net Loss per Share	Basic and Diluted Net Loss per Share	$	(0.09)	$	(0.10)	$	(0.17)	$	(0.22)	Basic and Diluted Net Loss per Share	$	(0.56)	$	(0.99)	$	(1.40)	$	(1.90)
Basic and Diluted Weighted Average Shares Outstanding	Basic and Diluted Weighted Average Shares Outstanding	93,703,492		69,428,574		93,647,583		68,473,407		Basic and Diluted Weighted Average Shares Outstanding	8,805,190		8,518,499		8,675,428		8,513,417

The accompanying notes are an integral part of the condensed consolidated financial statements.

ROCKWELL MEDICAL, INC. AND SUBSIDIARIES

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(~~Dollars in~~In Thousands)


		Three Months Ended June 30, 2021		Three Months Ended June 30, 2020		Six Months Ended June 30, 2021		Six Months Ended June 30, 2020			Three Months Ended June 30, 2022		Three Months Ended June 30, 2021		Six Months Ended June 30, 2022		Six Months Ended June 30, 2021

Net Loss	Net Loss	$	(8,400)	$	(6,892)	$	(16,152)	$	(14,876)	Net Loss	$	(4,967)	$	(8,400)	$	(12,128)	$	(16,152)
Unrealized Loss on Available-for-Sale Debt Instrument Investments		(1)		(6)		(8)		(13)
Unrealized Gain (Loss) on Available-for-Sale Debt Instrument Investments										Unrealized Gain (Loss) on Available-for-Sale Debt Instrument Investments	—		(1)		—		(8)
Foreign Currency Translation Adjustments	Foreign Currency Translation Adjustments	0		1		3		7		Foreign Currency Translation Adjustments	(2)		—		(3)		3
Comprehensive Loss	Comprehensive Loss	$	(8,401)	$	(6,897)	$	(16,157)	$	(14,882)	Comprehensive Loss	$	(4,969)	$	(8,401)	$	(12,131)	$	(16,157)

The accompanying notes are an integral part of the condensed consolidated financial statements.

ROCKWELL MEDICAL, INC. AND SUBSIDIARIES

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY

(Dollars in Thousands)


		COMMON STOCK			ADDITIONAL PAID-IN CAPITAL		ACCUMULATED DEFICIT		ACCUMULATED OTHER COMPREHENSIVE INCOME		TOTAL STOCKHOLDERS' EQUITY			PREFERRED STOCK			COMMON STOCK			ADDITIONAL PAID-IN CAPITAL		ACCUMULATED DEFICIT		ACCUMULATED OTHER COMPREHENSIVE INCOME		TOTAL STOCKHOLDERS' (DEFICIT)
		SHARES	AMOUNT											SHARES	AMOUNT		SHARES	AMOUNT
Balance as of January 1, 2021		93,573,165	$	9	$	371,510	$	(337,406)	$	57	$	34,170
Balance as of January 1, 2022													Balance as of January 1, 2022	—	$	—	8,544,225	$	1	$	372,562	$	(370,080)	$	52	$	2,535
Net Loss	Net Loss	—	—		—		(7,752)		—		(7,752)		Net Loss	—	—		—	—		—		(7,162)		—		(7,162)
Unrealized Loss on Available-for-Sale Investments		—	—		—		—		(7)		(7)

Foreign Currency Translation Adjustments	Foreign Currency Translation Adjustments	—	—		—		—		3		3		Foreign Currency Translation Adjustments	—	—		—	—		—		—		(1)		(1)

Stock-based Compensation	Stock-based Compensation	26,354	—		(236)		—		—		(236)		Stock-based Compensation	—	—		—	—		(179)		—		—		(179)
Balance as of March 31, 2021		93,599,519	$	9	$	371,274	$	(345,158)	$	53	$	26,178
Balance as of March 31, 2022													Balance as of March 31, 2022	—	$	—	8,544,225	$	1	$	372,383	$	(377,242)	$	51	$	(4,807)
Net Loss	Net Loss	—	—		—		(8,400)		—		(8,400)		Net Loss	—	—		—	—		—		(4,967)		—		(4,967)
Unrealized Loss on Available-for-Sale Investments		—	—		—		—		(1)		(1)

Foreign Currency Translation Adjustments													Foreign Currency Translation Adjustments	—	—		—	—		—		—		(2)		(2)
Issuance of common stock, net of offering costs/Public Offering													Issuance of common stock, net of offering costs/Public Offering	—	—		844,613	—		14,893		—		—		14,893
Issuance of common stock, net of offering costs/At-the-Market Offering													Issuance of common stock, net of offering costs/At-the-Market Offering	—	—		7,500	—		15		—		—		15
Issuance of preferred stock, net of offering costs													Issuance of preferred stock, net of offering costs	15,000	—		—	—		14,916		—		—		14,916

Vesting of Restricted Stock Units Issued, net of taxes withheld	Vesting of Restricted Stock Units Issued, net of taxes withheld	211,862	—		(7)		—		—		(7)		Vesting of Restricted Stock Units Issued, net of taxes withheld	—	—		10,958	—		—		—		—		—

Stock-based Compensation expense		—	—		433		—		—		433
Balance as of June 30, 2021		93,811,381	$	9	$	371,700	$	(353,558)	$	52	$	18,203
Stock-based Compensation and modification expense													Stock-based Compensation and modification expense	—	—		—	—		97		—		—		97
Balance as of June 30, 2022													Balance as of June 30, 2022	15,000	$	—	9,407,296	$	1	$	402,304	$	(382,209)	$	49	$	20,145

The accompanying notes are an integral part of the condensed consolidated financial statements.

ROCKWELL MEDICAL, INC. AND SUBSIDIARIES

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY

(Dollars in Thousands)


		COMMON STOCK			ADDITIONAL PAID-IN CAPITAL		ACCUMULATED DEFICIT		ACCUMULATED OTHER COMPREHENSIVE INCOME		TOTAL STOCKHOLDERS' EQUITY			PREFERRED STOCK			COMMON STOCK			ADDITIONAL PAID-IN CAPITAL		ACCUMULATED DEFICIT		ACCUMULATED OTHER COMPREHENSIVE INCOME		TOTAL STOCKHOLDERS' EQUITY
		SHARES	AMOUNT											SHARES	AMOUNT		SHARES	AMOUNT
Balance as of January 1, 2020		65,378,890	$	7	$	326,777	$	(306,516)	$	52	$	20,320
Balance as of January 1, 2021													Balance as of January 1, 2021	—	$	—	8,506,651	$	1	$	371,518	$	(337,406)	$	57	$	34,170
Net Loss	Net Loss	—	—		—		(7,984)		—		(7,984)		Net Loss	—	—		—	—		—		(7,752)		—		(7,752)
Unrealized Loss on Available-for-Sale Investments	Unrealized Loss on Available-for-Sale Investments	—	—		—		—		(7)		(7)		Unrealized Loss on Available-for-Sale Investments	—	—		—	—		—		—		(7)		(7)
Foreign Currency Translation Adjustments	Foreign Currency Translation Adjustments	—	—		—		—		6		6		Foreign Currency Translation Adjustments	—	—		—	—		—		—		3		3
Issuance of common stock, net of offering costs/Bought Deal		3,670,212	—		8,003		—		—		8,003
Issuance of Warrants related to Debt Financing		—	—		501		—		—		501

Stock-based Compensation	Stock-based Compensation	—	—		935		—		—		935		Stock-based Compensation	—	—		2,396	—		(236)		—		—		(236)
Balance as of March 31, 2020		69,049,102	$	7	$	336,216	$	(314,500)	$	51	$	21,774
Balance as of March 31, 2021													Balance as of March 31, 2021	—	$	—	8,509,047	$	1	$	371,282	$	(345,158)	$	53	$	26,178
Net Loss	Net Loss	—	—		—		(6,892)		—		(6,892)		Net Loss	—	—		—	—		—		(8,400)		—		(8,400)
Unrealized Loss on Available-for-Sale Investments	Unrealized Loss on Available-for-Sale Investments	—	—		—		—		(6)		(6)		Unrealized Loss on Available-for-Sale Investments	—	—		—	—		—		—		(1)		(1)
Foreign Currency Translation Adjustments		—	—		—		—		1		1
Issuance of common stock, net of offering costs/Public Offering		987,716	—		1,978		—		—		1,978

Vesting of Restricted Stock Units Issued, net of taxes withheld	Vesting of Restricted Stock Units Issued, net of taxes withheld	120,104	—		(19)		—		—		(19)		Vesting of Restricted Stock Units Issued, net of taxes withheld	—	—		19,260	—		(7)		—		—		(7)
Warrant Modification Expense		—	—		837		—		—		837

Stock-based Compensation	Stock-based Compensation	—	—		(1,461)		—		—		(1,461)		Stock-based Compensation	—	—		—	—		433		—		—		433
Balance as of June 30, 2020		70,156,922	$	7	$	337,551	$	(321,392)	$	46	$	16,212
Balance as of June 30, 2021													Balance as of June 30, 2021	—	$	—	8,528,307	$	1	$	371,708	$	(353,558)	$	52	$	18,203

The accompanying notes are an integral part of the condensed consolidated financial statements.

ROCKWELL MEDICAL, INC. AND SUBSIDIARIES

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Dollars in Thousands)

For the six months ended June 30, ~~2021~~2022 and ~~2020~~2021


		2021		2020			Six Months Ended June 30, 2022		Six Months Ended June 30, 2021

Cash Flows From Operating Activities:	Cash Flows From Operating Activities:					Cash Flows From Operating Activities:
Net Loss	Net Loss	$	(16,152)	$	(14,876)	Net Loss	$	(12,128)	$	(16,152)
Adjustments To Reconcile Net Loss To Net Cash Used In Operating Activities:	Adjustments To Reconcile Net Loss To Net Cash Used In Operating Activities:					Adjustments To Reconcile Net Loss To Net Cash Used In Operating Activities:
Depreciation and Amortization	Depreciation and Amortization	385		408		Depreciation and Amortization	279		385
Stock-based Compensation	Stock-based Compensation	197		(526)		Stock-based Compensation	(82)		197
Warrant Modification Expense		0		837

Increase in Inventory Reserves	Increase in Inventory Reserves	89		12		Increase in Inventory Reserves	10		89
Amortization of Right of Use Asset	Amortization of Right of Use Asset	857		748		Amortization of Right of Use Asset	1,027		857
Amortization of Debt Financing Costs and Accretion of Debt Discount	Amortization of Debt Financing Costs and Accretion of Debt Discount	184		108		Amortization of Debt Financing Costs and Accretion of Debt Discount	184		184
Loss on Disposal of Assets		8		6
Realized Loss (Gain) on Sale of Investments Available-for-Sale		1		(4)
(Gain) Loss on Disposal of Assets						(Gain) Loss on Disposal of Assets	(2)		8
Realized (Gain) Loss on Sale of Investments Available-for-Sale						Realized (Gain) Loss on Sale of Investments Available-for-Sale	(4)		1
Foreign Currency Translation Adjustment	Foreign Currency Translation Adjustment	3		6		Foreign Currency Translation Adjustment	(3)		3
Changes in Assets and Liabilities:	Changes in Assets and Liabilities:					Changes in Assets and Liabilities:
(Increase) Decrease in Accounts Receivable, net		(1,186)		637
Increase in Accounts Receivable, net						Increase in Accounts Receivable, net	(2,177)		(1,186)

Increase in Inventory	Increase in Inventory	(799)		(1,302)		Increase in Inventory	(1,063)		(799)
Decrease (Increase) in Prepaid and Other Assets		1,293		(608)
Increase in Accounts Payable		777		295
Decrease in Settlement Payable		0		(104)
Decrease in Prepaid and Other Assets						Decrease in Prepaid and Other Assets	1,275		1,293
(Decrease) Increase in Accounts Payable						(Decrease) Increase in Accounts Payable	(797)		777

Decrease in Lease Liability	Decrease in Lease Liability	(839)		(703)		Decrease in Lease Liability	(969)		(839)
Decrease in Other Liabilities	Decrease in Other Liabilities	(1,163)		(96)		Decrease in Other Liabilities	(385)		(1,163)
Decrease in Deferred License Revenue	Decrease in Deferred License Revenue	(1,088)		(992)		Decrease in Deferred License Revenue	(883)		(1,088)
Changes in Assets and Liabilities	Changes in Assets and Liabilities	(3,005)		(2,873)		Changes in Assets and Liabilities	(4,999)		(3,005)
Cash Used In Operating Activities	Cash Used In Operating Activities	(17,433)		(16,154)		Cash Used In Operating Activities	(15,718)		(17,433)
Cash Flows From Investing Activities:	Cash Flows From Investing Activities:					Cash Flows From Investing Activities:
Purchase of Investments Available-for-Sale	Purchase of Investments Available-for-Sale	(13,765)		(16,514)		Purchase of Investments Available-for-Sale	(2,810)		(13,765)
Sale of Investments Available-for-Sale	Sale of Investments Available-for-Sale	15,181		17,497		Sale of Investments Available-for-Sale	11,972		15,181
Purchase of Equipment	Purchase of Equipment	(281)		(283)		Purchase of Equipment	(80)		(281)

Cash Provided By Investing Activities	Cash Provided By Investing Activities	1,135		700		Cash Provided By Investing Activities	9,082		1,135
Cash Flows From Financing Activities:	Cash Flows From Financing Activities:					Cash Flows From Financing Activities:
Proceeds from Term Loan		0		22,500
Debt Issuance Costs		0		(1,343)

Payments on Debt						Payments on Debt	(5,250)		—
Payments on Short Term Note Payable	Payments on Short Term Note Payable	0		(763)		Payments on Short Term Note Payable	(439)		—
Proceeds from the Issuance of Common Stock / Public Offering		0		8,148
Offering Costs from the Issuance of Common Stock / Public Offering		0		(144)
Proceeds from the Issuance of Common Stock / At-the-Market Offering		0		2,034
Offering Costs from the Issuance of Common Stock / At-the-Market Offering		0		(56)
Proceeds from the Issuance of Common Stock						Proceeds from the Issuance of Common Stock	15,016		—
Offering Costs from the Issuance of Common Stock						Offering Costs from the Issuance of Common Stock	(106)		—

Proceeds from the Issuance of Preferred Shares						Proceeds from the Issuance of Preferred Shares	15,000		—
Offering Costs from the Issuance of Preferred Stock						Offering Costs from the Issuance of Preferred Stock	(85)		—

Repurchase of Common Stock to Pay Employee Withholding Taxes	Repurchase of Common Stock to Pay Employee Withholding Taxes	(6)		(19)		Repurchase of Common Stock to Pay Employee Withholding Taxes	—		(6)
Cash (Used In) Provided By Financing Activities		(6)		30,357
Cash Provided by (Used In) Financing Activities						Cash Provided by (Used In) Financing Activities	24,136		(6)

(Decrease) Increase in Cash and Cash Equivalents		(16,304)		14,903
Increase (Decrease) in Cash and Cash Equivalents						Increase (Decrease) in Cash and Cash Equivalents	17,500		(16,304)
Cash and Cash Equivalents at Beginning of Period	Cash and Cash Equivalents at Beginning of Period	48,682		11,794		Cash and Cash Equivalents at Beginning of Period	13,280		48,682
Cash and Cash Equivalents at End of Period	Cash and Cash Equivalents at End of Period	$	32,378	$	26,697	Cash and Cash Equivalents at End of Period	$	30,780	$	32,378

Supplemental Disclosure of Cash Flow Information:	Supplemental Disclosure of Cash Flow Information:					Supplemental Disclosure of Cash Flow Information:
Cash Paid for Interest	Cash Paid for Interest	$	982	$	410	Cash Paid for Interest	$	998	$	982
Supplemental Disclosure of Noncash Investing and Financing Activities:	Supplemental Disclosure of Noncash Investing and Financing Activities:					Supplemental Disclosure of Noncash Investing and Financing Activities:
Change in Unrealized Loss on Marketable Securities Available-for-Sale	Change in Unrealized Loss on Marketable Securities Available-for-Sale	$	(7)	$	(12)	Change in Unrealized Loss on Marketable Securities Available-for-Sale	$	—	$	(7)

Fair Value of Warrants issued related to Debt Financing		$	0	$	501

The accompanying notes are an integral part of the condensed consolidated financial statements.

ROCKWELL MEDICAL, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

1. Description of Business

Rockwell Medical, Inc. ("Rockwell Medical," ~~"Rockwell"~~"Rockwell," or the "Company") is a ~~commercial-stage, biopharmaceutical~~commercial healthcare company ~~developing~~focused on providing life-sustaining products for patients suffering from blood disorders and commercializing our next-generation parenteral iron technology platform, ferric pyrophosphate citrate (“FPC”), which we believe has the potential to lead to transformative treatments for iron deficiency in multiple disease states, that we believe could reduce healthcare costs and improve patients’ lives. We are also one of the two major suppliers of life saving hemodialysis concentrate products to kidney dialysis clinics in the United States.

We have two novel, FDA approved therapies, Triferic and Triferic AVNU, which are the first two products developed from our FPC platform. We are marketing both products to kidney dialysis centers for their patients receiving dialysis. In 2021, we intend to advance our FPC platform strategy outside of dialysis by starting a Phase II trial for the treatment of iron deficiency anemia in patients outside of dialysis, who are receiving long-term and or chronic intravenous medications for various therapeutic needs in the home infusion setting. In our R&D pipeline, we are also exploring FPC’s impact in the treatment of hospitalized patients with acute heart failure,diseases associated with the ~~potential to begin another Phase 2 trial in these patients in 2022.~~

~~We are~~kidney. Rockwell is a revenue-generating business and the second largest supplier of acid and bicarbonate concentrates for dialysis patients in the United States. Hemodialysis is the most common form of end-stage renal disease treatment and is usually performed at a freestanding outpatient dialysis center, at a hospital-based outpatient center, or at the patient’s home.

We manufacture our hemodialysis concentrates under cGMP regulations at our 3 facilities in Michigan, Texas, and South Carolina totaling approximately 175,000 square feet, from which we deliver these products to dialysis clinics throughout the United States with our own delivery fleet as well as third parties. We also manufacture mixers that are used by clinics in our Iowa facility. Rockwell has developed a core expertise in manufacturing and delivering hemodialysis concentrates, and has built a longstanding reputation for reliability, quality, and excellent customer service.

Rockwell commercializes Triferic in the United States, ~~generating approximately $60 million~~an FDA-approved treatment indicated for the replacement of iron to maintain hemoglobin in ~~annual revenue. The Company's reputation~~adult patients with hemodialysis-dependent chronic kidney disease. Rockwell also has a number of partnerships with companies seeking to develop and commercialize Triferic outside the United States. Rockwell is working closely with these partners to progress these programs.

We have an emerging portfolio of drug development candidates we are pursuing. Rockwell is developing a next-generation, proprietary parenteral iron technology platform, Ferric Pyrophosphate Citrate (“FPC”). We believe our FPC platform has several advantages over other parenteral iron therapies by immediately providing bioavailable iron for ~~excellent service, quality,~~critical body processes once it is administered. Rockwell is moving product candidates derived from this platform into the clinic to treat iron-deficiency anemia in the home infusion setting and ~~reliability is based on over 25 years of service to kidney dialysis centers. Our approximately 300~~for acute heart failure.

Together, with our dedicated employees ~~as well as a management team with experience~~and deep expertise in manufacturing and logistics and pharmaceutical development and ~~commercialization gives us a solid foundation upon which~~commercialization. Rockwell is well-positioned to ~~grow.~~realize sustainable business growth and support our mission to provide life-sustaining products for patients suffering from blood disorders and diseases associated with the kidney.

ROCKWELL MEDICAL, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

2. Liquidity and Capital Resources

Since inception, Rockwell has incurred significant net losses and has funded its operations primarily through revenue from commercial products, proceeds from the issuance of debt and equity securities and payments from partnerships. At June 30, 2021, Rockwell had an accumulated deficit of approximately $353.6 million and stockholders' equity of $18.2 million. As of June 30, ~~2021,~~2022, Rockwell had approximately ~~$41.0~~$30.8 million of cash and cash equivalents ~~and investments available-for-sale,~~ and working capital of ~~$18.4~~$28.7 million. Net cash used in operating activities for the six months ended June 30, ~~2021~~2022 was approximately ~~$17.4~~$15.7 million. Based on the currently available working capital and capital raises described below, management believes the Company currently has sufficient funds to meet its operating requirements for at least the next twelve months from the date of the filing of this report.

On April 6, 2022, the Company and DaVita, Inc. ("DaVita") entered into an amendment (the "Amendment") to the Products Purchase Agreement, dated July 1, 2019, under which the Company supplies DaVita with certain dialysis concentrates. Under the Amendment, the Company and DaVita agreed to certain price increases, effective May 1, 2022, as well as the pass-through of certain inflationary costs, determined on a quarterly basis. Certain costs are subject to a cap. The Amendment also requires the Company to implement certain cost containment and cost-cutting measures. The Amendment contains certain covenants with respect to the Company’s ongoing operations, including a minimum cash covenant of $10 million, or we will be in default under the Products Purchase Agreement. An event of default could result in termination of that agreement.

On April 6, 2022, the Company and DaVita entered into a Securities Purchase Agreement (the “SPA”), pursuant to which the Company issued $15 million of preferred stock to DaVita in two separate tranches. The Company initially issued 7,500 shares of a newly designated series of preferred stock, which is designated “Series X Convertible Preferred Stock” (the “Series X Preferred Stock”) for gross proceeds of $7.5 million. On June 15, 2022, the Company issued to DaVita an additional 7,500 shares of Series X Preferred Stock in a second closing (the “Second Tranche”) for an additional $7.5 million. The Second Tranche was conditioned upon the Company raising an additional $15 million in capital within a certain timeline, which took place on June 2, 2022.

On April 8, 2022, the Company entered into a sales agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), pursuant to which the Company may offer and sell from time to time up to $12,200,000 of shares of Company’s common stock through the Agent. The offering and sale of such shares has been registered under the Securities Act of 1933, as amended (the “Securities Act”), pursuant to the Company’s Registration Statement on Form S-3 (File No. 333-259923) (the “Registration Statement”), which was originally filed with the Securities and Exchange Commission (“SEC”) on September 30, 2021 and declared effective by the SEC on October 8, 2021, the base prospectus contained within the Registration Statement, and a prospectus supplement that was filed with the SEC on April 8, 2022. As of June 30, 2022, the Company sold 7,500 shares of its common stock pursuant to the Sales Agreement for gross proceeds of $15,135, at a weighted average selling price of approximately $2.02 The Company paid $378 in commissions and offering fees. Approximately $12.2 million remains available for sale under the ATM facility.

On May 30, 2022, the Company entered into a Securities Purchase Agreement (the “RD Purchase Agreement”) with the purchaser named therein (the “Purchaser”), pursuant to which the Company agreed to issue and sell, in a registered direct offering (the “Offering”), 844,613 shares of its common stock at price of $1.39 per share, and prefunded warrants to purchase up to an aggregate of 7,788,480 shares of common stock (the “Pre-Funded Warrants” and the shares of common stock underlying the Pre-Funded Warrants, the “Warrant Shares”). The purchase price of each Pre-Funded Warrant was equal to the price at which a share of common stock was sold to the public in the Offering, minus $0.0001, and the exercise price of each Pre-Funded Warrant is $0.0001 per share.

Also on May 30, 2022, concurrently with the Offering, the Company entered into a Securities Purchase Agreement with the Purchaser (the “PIPE Purchase Agreement”) relating to the offering and sale (the “Private Placement”) of warrants to purchase up to a total of 9,900,990 shares of common stock and pre-funded warrants to purchase up to a total of 1,267,897 shares of common stock (the “PIPE Warrants”). Each warrant was sold at a price of $0.125 per underlying warrant share and is exercisable at an exercise price of $1.39 per share. The purchase price of each Pre-Funded Warrant was equal to the price at which a share of common stock was sold to the public in the Offering, minus $0.0001, and the exercise price of each prefunded warrant is $0.0001 per share. The Offering and the Private Placement closed on June 2, 2022. The net proceeds to the Company from the Offering and the Private Placement were approximately $14.9 million, after deducting fees and expenses.

The Company expects it will require additional capital to sustain its operations and make the investments it needs to execute its strategic plan in developing FPC for iron deficiency anemia in patients undergoing home infusion and for progressing our pipeline development program of new indications for our FPC platform. If the Company attempts to obtain additional debt or equity financing, the Company cannot assume such financing will be available on favorable terms, if at all.

Currently, because the Company's public float is less than $75 million, we are subject to the baby shelf limitations under our current registration statement on Form S-3, which limit the amount we may offer under our Form S-3. This could limit our ability to raise capital under this registration statement.

As previously reported, on June 11, 2021, the Company received written notice (the "Notification Letter") from the Nasdaq Stock Market ("Nasdaq") notifying the Company it is not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5450(a)(1) for continued listing on the Nasdaq Global Market. Nasdaq Listing Rule 5450(a)(1) requires listed securities maintain a minimum closing bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum closing bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the closing bid price of the Company's common stock for the 30 consecutive business days prior to the date of the Notification Letter, the Company did not meet the minimum closing bid price requirement. The Notification Letter provided for 180 calendar days, or until December 8, 2021, for the Company to regain compliance with Nasdaq Listing Rule 5450(a)(1). To regain compliance, the closing bid price of the Company’s common stock must be at least $1.00 per share for a minimum of 10 consecutive business days at any time prior to December 8, 2021. The Company was not able to meet the minimum compliance requirements set forth by Nasdaq by December 8, 2021.

On December 9, 2021, the Company received a written notice from Nasdaq indicating the Company’s application to transfer its listing venue from The Nasdaq Global Market to The Nasdaq Capital Market for its common stock had been approved. The Company’s common stock commenced trading on The Nasdaq Capital Market at the opening of business on December 10, 2021 under the symbol “RMTI.”

Also on December 9, 2021, the Company received written notice that Nasdaq has determined the Company was eligible for an additional 180-day extension, or until June 6, 2022, to regain compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. To regain compliance, the closing bid price of the Company’s common stock must be at least $1.00 per share for a minimum of 10 consecutive business days at any time prior to June 6, 2022. On May 13, 2022, the Company effected a reverse stock split and on May 31, 2022 Nasdaq notified the Company it had regained compliance with the minimum bid price requirement (see Note 3 for further detail).

In addition, the Company is subject to certain covenants and cure provisions under its Loan Agreement with Innovatus. As of the date of this report, the Company is in compliance with all ~~covenants. As a result of the ongoing COVID-19 pandemic and its effect on the Company's sales activities, among other factors, the Company may not be able to satisfy such~~ covenants over the next 12 months. However, based on the foregoing, the Company has classified amounts payable under the Loan Agreement as a current liability. If and when the Company reaches an agreement with Innovatus to avoid an event of default, the amounts payable under the Loan Agreement will be reclassified. The financial statements for June 30, 2021, have been prepared with the assumption that the Company will be able to agree to an appropriate remedy during the applicable cure period for any future breaches of operating covenants. If the Company is unable to comply with the covenants under the Loan Agreement, it would pursue all available cure options in order to regain compliance (See Note 1514 for further detail).

The Company expects it will require additional capital to sustain its operations and make the investments it needs to execute its strategic plan, including the commercialization of Triferic (dialysate) and Triferic AVNU in dialysis, generating additional data for Triferic in dialysis, developing FPC for iron deficiency anemia in patients undergoing home infusion and for progressing our pipeline development program of new indications for its FPC platform. If the Company is unable to generate sufficient revenue from sales of its commercial products and from partnerships, the Company will need to obtain additional equity or debt financing. If the Company attempts to obtain additional debt or equity financing, the Company cannot assume that such financing will be available on favorable terms, if at all.

Based on the currently available working capital and managements assumption that the Company will be able to agree to an appropriate remedy, management believes the Company currently has sufficient funds to meet its operating requirements for at least the next twelve months from the date of the filing of this report.

~~ROCKWELL MEDICAL, INC. AND SUBSIDIARIES~~

~~Notes to Condensed Consolidated Financial Statements~~

~~(Unaudited)~~

The COVID-19 pandemic and resulting domestic and global disruptions, particularly in the supply chain and labor market, among other areas, have adversely affected ~~Rockwell's~~our business and operations, including, but not limited to, our sales and marketing efforts and our research and development activities, our plant and transportation operations and the operations of third parties upon whom the Company relies. Quarantines, shelter-in-place, executive and similar government orders and the recent surge in infections domestically may continue to negatively impact Rockwell's sales and marketing activities, particularly if its sales representatives are unable to interact with current and potential customers to the same extent as before onset of the COVID-19 pandemic.we rely. The Company's international business development activities may also continue to be negatively impacted by ~~COVID-19, especially with the recent surge in infections internationally, ongoing international travel restrictions and quarantines or shelter-in-place orders.~~COVID-19.

The COVID-19 pandemic ~~the domestic~~ and ~~international surge in infections and~~the resulting global disruptions and recent inflationary pressures have caused significant volatility in financial and credit markets. Rockwell has utilized a range of financing methods to fund its operations in the past; however, current conditions in the financial and credit markets may limit the availability of funding, refinancing or increase the cost of funding. Due to the rapidly evolving nature of the global situation, it is not possible to predict the extent to which these conditions could adversely affect the Company's liquidity and capital resources in the future.

ROCKWELL MEDICAL, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

3. Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements

The accompanying condensed consolidated financial statements have been prepared in accordance with the accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the instructions to Form 10-Q and Rule 10-01 of Regulation S-X of the U. S. Securities and Exchange Commission (“SEC”) and on the same basis as the Company prepares its annual audited consolidated financial statements.

The condensed consolidated balance sheet at June 30, ~~2021,~~2022, condensed consolidated statements of operations for the three and six months ended June 30, ~~2021~~2022 and ~~2020,~~2021, condensed consolidated statements of comprehensive loss for the three and six months ended June 30, ~~2021~~2022 and ~~2020,~~2021, condensed consolidated statement of changes in stockholders' equity for the three and six months ended June 30, ~~2021~~2022 and ~~2020,~~2021, and condensed consolidated statements of cash flows for the six months ended June 30, ~~2021~~2022 and ~~2020~~2021 are unaudited, but include all adjustments, consisting of normal recurring adjustments, ~~that~~ the Company considers necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The results for the three and six months ended June 30, ~~2021~~2022 are not necessarily indicative of results to be expected for the year ending December 31, ~~2021~~2022 or for any future interim period. The condensed consolidated balance sheet at December 31, ~~2020~~2021 has been derived from audited financial statements, however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying condensed consolidated financial statements should be read in conjunction with the audited financial statements for the year ended December 31, ~~2020~~2021 and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, ~~2020~~2021 as filed with the SEC on ~~March 31, 2021.~~April 8, 2022. The Company’s consolidated subsidiaries consisted of its wholly-owned subsidiaries, Rockwell Transportation, Inc. and Rockwell Medical India Private Limited.

The accompanying condensed consolidated interim financial statements include the accounts of the Company and its subsidiaries. All material intercompany balances and transactions have been eliminated in consolidation.

Reverse Stock Split

On May 9, 2022, the stockholders of the Company authorized our Board of Directors to effect a reverse stock split of all outstanding shares of common stock. The Board of Directors subsequently approved the implementation of a reverse stock split as a ratio of one-for-eleven shares, which became effective on May 13, 2022. The Company’s outstanding stock options were also adjusted to reflect the one-for-eleven reverse stock split of the Company’s common stock. Outstanding stock options were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased. The reverse stock split resulted in an adjustment to the Series X convertible preferred stock conversion prices to reflect a proportional decrease in the number of shares of common stock to be issued upon conversion. All share and per share data in these condensed consolidated financial statements and related notes hereto have been retroactively adjusted to account for the effect of the reverse stock split for the three and six month periods ended June 30, 2022 and 2021, respectively, and the balance sheet at June 30, 2022 and December 31, 2021.

Use of Estimates

The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates.

Leases

The Company accounts for its leases under Accounting Standards Codification (“ASC”) 842, Leases. Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the consolidated balance sheet as both a right-of-use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company’s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right-of-use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right-of-use asset result in straight-line rent expense over the lease term. Variable lease expenses, if any, are recorded when incurred.

~~ROCKWELL MEDICAL, INC. AND SUBSIDIARIES~~

~~Notes to Condensed Consolidated Financial Statements~~

~~(Unaudited)~~

In calculating the right-of-use asset and lease liability, the Company elects to combine lease and non-lease components. The Company excludes short-term leases having initial terms of 12 months or less from the new guidance as an accounting policy election and recognizes rent expense on a straight-line basis over the lease term.

Loss Per Share

ASC 260, Earnings Per Share, requires dual presentation of basic and diluted earnings per share (“EPS”), with a reconciliation of the numerator and denominator of the basic EPS computation to the numerator and denominator of the diluted EPS computation. Basic EPS excludes dilution. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that are then sharing in the earnings of the entity.

Basic net loss per share ~~of common stock excludes dilution and~~ is ~~computed~~calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding ~~during~~for the ~~period.~~period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common ~~stock reflects~~shares outstanding plus the effect of dilutive potential ~~dilution that could occur if securities or other contracts to issue~~common shares outstanding during the period determined using the treasury-stock and if-converted methods. For purposes of the diluted net loss per share calculation, common stock ~~were exercised or converted into common~~warrants, unvested restricted stock ~~or resulted in~~units and stock options are considered to be potentially dilutive securities but are excluded from the ~~issuance~~calculation of ~~common stock that then shared in the earnings of the entity unless inclusion of such shares~~diluted net loss per share because their effect would be ~~anti-dilutive. The Company has only incurred losses,~~anti-dilutive, and therefore, basic and diluted net loss per share iswere the ~~same. Securities~~same for all periods presented.

The following table sets forth the outstanding potentially dilutive securities that ~~could potentially dilute net income per share in~~have been excluded from the ~~future that were not included in the computation~~calculation of diluted net loss per share ~~were as follows:~~for the six months ended June 30, 2022 and 2021, respectively, because to do so would be anti-dilutive (in common equivalent shares):


		As of June 30,			As of June 30,
		2021	2020		2022	2021
Options to purchase common stock	Options to purchase common stock	6,070,801	6,225,562	Options to purchase common stock	423,317	551,891
Unvested restricted stock awards	Unvested restricted stock awards	78,300	146,800	Unvested restricted stock awards	891	7,118
Unvested restricted stock units	Unvested restricted stock units	342,604	503,395	Unvested restricted stock units	125,000	31,146
Preferred stock conversion to common stock				Preferred stock conversion to common stock	1,363,636	—
Warrants to purchase common stock	Warrants to purchase common stock	26,426,863	3,248,054	Warrants to purchase common stock	21,359,809	2,402,442
Total	Total	32,918,568	10,123,811	Total	23,272,653	2,992,597

Adoption of Recent Accounting Pronouncements

The Company continually assesses new accounting pronouncements to determine their applicability. When it is determined ~~that~~ a new accounting pronouncement affects the Company’s financial reporting, the Company undertakes a review to determine the consequences of the change to its consolidated financial statements and assures ~~that~~ there are sufficient controls in place to ascertain ~~that~~ the Company’s consolidated financial statements properly reflect the change.

In ~~April 2021,~~August 2020, the ~~Financial~~FASB issued ASU No. 2020-06, “Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging— Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting ~~Standards Board ("FASB") recently issued Accounting Standards Update ("ASU") 2021-04~~for Convertible Instruments and Contracts in an Entity’s Own Equity”, which simplifies the accounting for convertible instruments by eliminating the requirement to ~~codify~~separate embedded conversion features from the ~~final consensus reached by~~host contract when the ~~Emerging Issues Task Force (EITF) on how an issuer should account~~conversion features are not required to be accounted for ~~modifications made to equity-classified written call options (hereafter referred to~~as derivatives under Topic 815, Derivatives and Hedging, or do not result in substantial premiums accounted for as paid-in capital. By removing the separation model, a convertible debt instrument will be reported as a ~~warrant~~single liability instrument with no separate accounting for embedded conversion features. This new standard also removes certain settlement conditions required for contracts to ~~purchase~~qualify for equity classification and simplifies the ~~issuer’s common stock). The guidance~~diluted earnings per share calculations by requiring an entity use the if-converted method and the effect of potential share settlement be included in diluted earnings per share calculations. This new standard will be effective for the ~~ASU requires the issuer to treat a modification of an equity-classified warrant that does not cause the warrant to become liability-classified as an exchange of the original warrant~~Company for ~~a new warrant. This guidance applies whether the modification~~fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is ~~structured as an amendment to the terms and conditions of the warrant or as termination of the original warrant and issuance of a new warrant.~~permitted, but no earlier than fiscal years beginning after December 15, 2020. The Company is ~~evaluating~~currently assessing the impact of adopting this ~~guidance~~standard on ~~its condensed~~the consolidated financial statements.

ROCKWELL MEDICAL, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

4. Revenue Recognition

The Company recognizes revenue under ASC 606, Revenue from Contracts with Customers. The core principle of the new revenue standard is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The following five steps are applied to achieve that core principle:

•Step 1: Identify the contract with the customer

•Step 2: Identify the performance obligations in the contract

•Step 3: Determine the transaction price

•Step 4: Allocate the transaction price to the performance obligations in the contract

~~ROCKWELL MEDICAL, INC. AND SUBSIDIARIES~~

~~Notes to Condensed Consolidated Financial Statements~~

~~(Unaudited)~~

•Step 5: Recognize revenue when the company satisfies a performance obligation

Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by us from a customer, are excluded from revenue.

Shipping and handling costs associated with outbound freight related to contracts with customers are accounted for as a fulfillment cost and are included in cost of sales when control of the goods transfers to the customer.

Nature of goods and services

The following is a description of principal activities from which the Company generates its revenue.

Product sales –The Company accounts for individual products and services separately if they are distinct (i.e., if a product or service is separately identifiable from other items and if a customer can benefit from it on its own or with other resources that are readily available to the customer). The consideration, including any discounts, is allocated between separate products and services based on their stand-alone selling prices. The stand-alone selling prices are determined based on the cost plus margin approach.

Drug and dialysis concentrate products are sold directly to dialysis clinics and to wholesale distributors in both domestic and international markets. Distribution and license agreements for which upfront fees are received are evaluated upon execution or modification of the agreement to determine if the agreement creates a separate performance obligation from the underlying product sales. For all existing distribution and license agreements, the distribution and license agreement is not a distinct performance obligation from the product sales. In instances where regulatory approval of the product has not been established and the Company does not have sufficient experience with the foreign regulatory body to conclude ~~that~~ regulatory approval is probable, the revenue for the performance obligation is recognized over the term of the license agreement (over time recognition). Conversely, when regulatory approval already exists or is probable, revenue is recognized at the point in time ~~that~~ control of the product transfers to the customer.

The Company received upfront fees under 5 distribution and license agreements that have been deferred as a contract liability. The amounts received from Wanbang Biopharmaceuticals Co., Ltd. (“Wanbang”), Sun Pharmaceutical Industries Ltd. ("Sun Pharma"), Jeil Pharmaceutical Co., Ltd. ("Jeil Pharma") and Drogsan Pharmaceuticals ("Drogsan Pharma") are recognized as revenue over the estimated term of the applicable distribution and license agreement as regulatory approval was not received and the Company did not have sufficient experience in China, India, ~~and~~ South Korea and Turkey, respectively, to determine ~~that~~ regulatory approval was probable as of the execution of the agreement. The amounts received from Baxter Healthcare Corporation (“Baxter”) are recognized as revenue at the point in time ~~that~~ the estimated product sales under the agreement occur.

For the business under the Company’s Distribution Agreement with Baxter (the “Baxter Agreement”), and for the majority of the Company’s international customers, the Company recognizes revenue at the shipping point, which is generally the Company’s plant or warehouse. For other business, the Company recognizes revenue based on when the customer takes control ~~or receipt~~ of the product. The amount of revenue recognized is based on the purchase order less returns and adjusted for any rebates, discounts, chargebacks or other amounts paid to customers. There were no such adjustments for the periods reported. Customers typically pay for the product based on customary business practices with payment terms averaging 30 days, while distributor payment terms average 45 days.

Disaggregation of revenue

Revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition.


In thousands of U.S. dollars ($)	Three Months Ended June 30, 2022						Six Months Ended June 30, 2022
Products By Geographic Area	Total		U.S.		Rest of World		Total		U.S.		Rest of World
Drug Revenues
Product Sales – Point-in-time	$	482	$	209	$	273	$	641	$	368	$	273
License Fee – Over time	65		—		65		127		—		127
Total Drug Products	547		209		338		768		368		400
Concentrate Products
Product Sales – Point-in-time	17,655		15,906		1,749		33,082		29,715		3,367
License Fee – Over time	480		480		—		956		956		—
Total Concentrate Products	18,135		16,386		1,749		34,038		30,671		3,367
Net Revenue	$	18,682	$	16,595	$	2,087	$	34,806	$	31,039	$	3,767

~~ROCKWELL MEDICAL, INC. AND SUBSIDIARIES~~

~~Notes to Condensed Consolidated Financial Statements~~

~~(Unaudited)~~

In thousands of U.S. dollars ($) Three Months Ended June 30, 2021 Six Months Ended June 30, 2021
Products By Geographic Area Total U.S. Rest of World Total U.S. Rest of World
Drug Revenues
Product Sales – Point-in-time $ 215 $ 215 $ 0 $ 439 $ 439 $ 0
License Fee – Over time 58 0 58 117 0 117
Total Drug Products 273 215 58 556 439 117
Concentrate Products
Product Sales – Point-in-time 14,379 13,026 1,353 29,084 26,227 2,857
License Fee – Over time 485 485 0 971 971 0
Total Concentrate Products 14,864 13,511 1,353 30,055 27,198 2,857
Net Revenue $ 15,137 $ 13,726 $ 1,411 $ 30,611 $ 27,637 $ 2,974


In thousands of U.S. dollars ($)	In thousands of U.S. dollars ($)	Three Months Ended June 30, 2020						Six Months Ended June 30, 2020						In thousands of U.S. dollars ($)	Three Months Ended June 30, 2021						Six Months Ended June 30, 2021
Products By Geographic Area	Products By Geographic Area	Total		U.S.		Rest of World		Total		U.S.		Rest of World		Products By Geographic Area	Total		U.S.		Rest of World		Total		U.S.		Rest of World
Drug Revenues	Drug Revenues													Drug Revenues
Product Sales – Point-in-time	Product Sales – Point-in-time	$	182	$	182	$	0	$	381	$	381	$	0	Product Sales – Point-in-time	$	215	$	215	$	—	$	439	$	439	$	—
License Fee – Over time	License Fee – Over time	56		0		56		112		0		112		License Fee – Over time	58		—		58		117		—		117
Total Drug Products	Total Drug Products	238		182		56		493		381		112		Total Drug Products	273		215		58		556		439		117
Concentrate Products	Concentrate Products													Concentrate Products
Product Sales – Point-in-time	Product Sales – Point-in-time	15,168		13,319		1,849		30,280		26,826		3,454		Product Sales – Point-in-time	14,379		13,026		1,353		29,084		26,227		2,857
License Fee – Over time	License Fee – Over time	490		490		0		980		980		0		License Fee – Over time	485		485		—		971		971		—
Total Concentrate Products	Total Concentrate Products	15,658		13,809		1,849		31,260		27,806		3,454		Total Concentrate Products	14,864		13,511		1,353		30,055		27,198		2,857
Net Revenue	Net Revenue	$	15,896	$	13,991	$	1,905	$	31,753	$	28,187	$	3,566	Net Revenue	$	15,137	$	13,726	$	1,411	$	30,611	$	27,637	$	2,974

Contract balances

The following table provides information about receivables, contract assets, and contract liabilities from contracts with customers.


In thousands of U.S. dollars ($)	In thousands of U.S. dollars ($)	June 30, 2021		December 31, 2020		In thousands of U.S. dollars ($)	June 30, 2022		December 31, 2021
Receivables, which are included in "Trade and other receivables"	Receivables, which are included in "Trade and other receivables"	$	5,357	$	4,171	Receivables, which are included in "Trade and other receivables"	$	8,090	$	5,913
Contract liabilities	Contract liabilities	$	9,103	$	10,190	Contract liabilities	$	7,274	$	8,157

There were ~~0 material~~no impairment losses recognized related to any receivables arising from the Company’s contracts with customers for the three and six months ended June 30, ~~2021~~2022 and ~~2020.~~2021.

For the three and six months ended June 30, ~~2021~~2022 and June 30, ~~2020,~~2021, the Company did not recognize any material bad-debt expense. There were 0no material contract assets recorded on the condensed consolidated balance sheet as of June 30, ~~2021~~2022 and December 31, ~~2020.~~2021. The Company does not generally accept returns of its concentrate products and 0no material reserve for returns of concentrate products was established as of June 30, ~~2021~~2022 or December 31, ~~2020.~~2021.

The contract liabilities primarily relate to upfront payments and consideration received from customers that are received in advance of the customer assuming control of the related products

Transaction price allocated to remaining performance obligations

For the three and six months ended June 30, ~~2021,~~2022, revenue recognized from performance obligations related to prior periods was not material.

~~ROCKWELL MEDICAL, INC. AND SUBSIDIARIES~~

~~Notes to Condensed Consolidated Financial Statements~~

~~(Unaudited)~~

Revenue expected to be recognized in any future year related to remaining performance obligations, excluding revenue pertaining to contracts that have an original expected duration of one year or less, contracts where revenue is recognized as invoiced, and contracts with variable consideration related to undelivered performance obligations, totaled ~~$9.1~~$7.3 million as of June 30, ~~2021.~~2022. The amount relates primarily to upfront payments and consideration received from customers ~~that are received~~ in advance of the customer assuming control of the related products. The Company applies the practical expedient in paragraph 606-10-50-14 and does not disclose information about remaining performance obligations ~~that have~~having original expected durations of one year or less. The Baxter Agreement includes minimum commitments of product sales over the duration of the agreement. Unfulfilled minimum commitments related to the Baxter Agreement are product sales of ~~$6.2~~$4.3 million as of June 30, ~~2021,~~2022, which is amortized ratably through expiration of the Baxter Agreement on October 2, 2024.

ROCKWELL MEDICAL, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

5. Investments - Available-for-Sale

As of June 30, 2022, all investment available-for-sale securities have been liquidated.

Investments available-for-sale consisted of the following as of ~~June 30, 2021 and~~ December 31, ~~2020~~2021 (table in thousands):

June 30, 2021
Amortized Cost Unrealized Gain Unrealized Loss Accrued Interest Income Fair Value
Available-for-Sale Securities
Bonds $ 8,558 $ 1 $ 0 $ 15 $ 8,574


		December 31, 2020											December 31, 2021
		Amortized Cost		Unrealized Gain		Unrealized Loss		Accrued Interest		Fair Value			Amortized Cost		Unrealized Gain		Unrealized Loss		Accrued Interest		Fair Value
Available-for-Sale Securities	Available-for-Sale Securities											Available-for-Sale Securities
Bonds	Bonds	$	9,987	$	3	$	0	$	7	$	9,997	Bonds	$	9,143	$	1	$	—	$	14	$	9,158

The fair value of investments available-for-sale are determined using quoted market prices from daily exchange-traded markets based on the closing price as of the balance sheet date and are classified as a Level 1 measurement under ASC 820 Fair Value Measurements.

As of ~~June 30, 2021 and~~ December 31, ~~2020,~~2021, the amortized cost and estimated fair value of our available-for-sale securities were due within one year.

6. Inventory

Components of inventory, net of reserves, as of June 30, ~~2021~~2022 and December 31, ~~2020~~2021 are as follows (table in thousands):


		June 30, 2021		December 31, 2020			June 30, 2022		December 31, 2021
Raw Materials	Raw Materials	$	3,598	$	3,112	Raw Materials	$	4,377	$	3,434
Work in Process	Work in Process	265		172		Work in Process	285		201
Finished Goods	Finished Goods	1,936		1,805		Finished Goods	1,990		1,964
Total	Total	$	5,799	$	5,089	Total	$	6,652	$	5,599

As of June 30, ~~2021,~~2022, the Company classified ~~$1.1~~$1.5 million of inventory as non-current, all of which was related to ~~Triferic~~TRIFERIC® or the active pharmaceutical ingredient and raw materials for ~~Triferic.~~TRIFERIC®. As of June 30, ~~2021,~~2022, the total ~~Triferic~~TRIFERIC® inventory net of reserve was ~~$1.7~~$1.5 million.

The ~~$1.7~~$1.5 million net value of ~~Triferic~~TRIFERIC® inventory consisted of $0.3 million of ~~Triferic~~TRIFERIC® (dialysate) finished goods with expiration dates ranging from ~~September 2021~~July 2022 to December 2023, ~~$0.5~~$0.4 million of ~~Triferic~~TRIFERIC® API with an estimated ~~remaining shelf~~useful life extending ~~beyond 2021,~~through 2023, and $0.9 million of raw materials for ~~Triferic~~TRIFERIC® with an estimated ~~remaining shelf~~useful life ~~extending beyond 2025.~~of 25 years.

7. Property and Equipment

As of June 30, 2022 and December 31, 2021, the Company’s property and equipment consisted of the following (table in thousands):


	June 30, 2022		December 31, 2021
Leasehold Improvements	$	1,250	$	1,204
Machinery and Equipment	5,874		5,864
Information Technology & Office Equipment	1,845		1,845
Laboratory Equipment	660		676
	9,629		9,589
Accumulated Depreciation	(7,340)		(7,103)
Property and Equipment, net	$	2,289	$	2,486

Depreciation expense for three months ended June 30, 2022 and 2021 was $0.1 million and $0.2 million, respectively. Depreciation expense for six months end June 30, 2022 and 2021 was $0.3 million and $0.4 million, respectively.

1312

ROCKWELL MEDICAL, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

~~7. Property and Equipment~~

~~As of June 30, 2021 and December 31, 2020, the Company’s property and equipment consisted of the following (table in thousands):~~

June 30,
2021 December 31,
2020
Leasehold Improvements $ 1,196 $ 1,196
Machinery and Equipment 5,684 5,475
Information Technology & Office Equipment 1,847 1,831
Laboratory Equipment 676 676
9,403 9,178
Accumulated Depreciation (6,874) (6,536)
Property and Equipment, net $ 2,529 $ 2,642

~~Depreciation expense for each of the three and six months ended June 30, 2021 and 2020 totaled $0.2 million and $0.4 million.~~

8. Accrued Liabilities

Accrued liabilities as of June 30, ~~2021~~2022 and December 31, ~~2020~~2021 consisted of the following (table in thousands):


		June 30, 2021		December 31, 2020			June 30, 2022		December 31, 2021
Accrued Research & Development Expense	Accrued Research & Development Expense	$	315	$	232	Accrued Research & Development Expense	$	110	$	366
Accrued Compensation and Benefits	Accrued Compensation and Benefits	1,420		2,500		Accrued Compensation and Benefits	2,439		1,791
Accrued Unvouchered Receipts	Accrued Unvouchered Receipts	647		755		Accrued Unvouchered Receipts	385		796
Accrued Workers Compensation	Accrued Workers Compensation	531		395		Accrued Workers Compensation	172		382
Other Accrued Liabilities	Other Accrued Liabilities	1,080		1,131		Other Accrued Liabilities	1,554		1,755
Total Accrued Liabilities	Total Accrued Liabilities	$	3,993	$	5,013	Total Accrued Liabilities	$	4,660	$	5,090

9. Deferred Revenue

In October 2014, the Company entered into the Baxter Agreement, ~~with Baxter~~which has a term of 10 years and received an upfront fee of $20 million. The upfront fee was recorded as deferred revenue and is being recognized based on the proportion of product shipments to Baxter in each period, compared with total expected sales volume over the term of the ~~Baxter Agreement, which expires in October 2024.~~Distribution Agreement. The Company recognized revenue of approximately $0.5 million and $1.0 million for each of the three and six months ended June 30, 2022 and 2021, ~~and 2020.~~respectively. Deferred revenue related to the Baxter Agreement totaled ~~$6.2~~$4.3 million as of June 30, ~~2021~~2022 and ~~$7.2~~$5.2 million as of December 31, ~~2020.~~

~~If a “Refund Trigger Event” occurs under the Baxter Agreement prior to December 31, 2021, Rockwell would be obligated to repay 25% of the upfront fee.~~2021.

In 2016, the Company entered into a distribution ~~and license~~ agreement with Wanbang (the "Wanbang Agreement") and received an upfront fee of $4.0 million. The upfront fee was recorded as deferred revenue and is being recognized as revenue based on the agreement term. The Company recognized revenue of approximately ~~$53,000 and~~ $0.1 million ~~revenue for~~during each of the three and six months ended June 30, ~~2021~~2022 and ~~2020.~~2021. Deferred revenue related to the Wanbang Agreement totaled ~~$2.6~~$2.4 million as of June 30, ~~2021~~2022 and ~~$2.7~~$2.5 million as of December 31, ~~2020.~~2021.

In January 2020, the Company entered into license and supply agreements with Sun Pharma (the "Sun Pharma Agreements"), for the rights to commercialize ~~Triferic~~TRIFERIC® (dialysate) (ferric pyrophosphate citrate) in India. Under the terms of the Sun Pharma Agreements, Sun Pharma will be the exclusive development and commercialization partner for Triferic (dialysate) in India, and the Company will supply the product to Sun Pharma. In consideration for the license, the Company received an upfront fee of $0.1 million, and will be eligible for milestone payments and royalties on net sales. A Joint Alliance Committee, comprised of members from the Company and Sun Pharma, will guide the development and execution for Triferic (dialysate) in

~~ROCKWELL MEDICAL, INC. AND SUBSIDIARIES~~

~~Notes to Condensed Consolidated Financial Statements~~

~~(Unaudited)~~

~~India. Sun Pharma will be responsible for all clinical and regulatory approval, as well as commercialization activities.~~million. The upfront fee was recorded as deferred revenue and is being recognized as revenue based on the agreement term. The Company recognized revenue of approximately $2,500 and $5,000 for each of the three and six months ended June 30, 2022 and 2021, ~~and 2020.~~respectively. Deferred revenue related to the Sun Pharma Agreement totaled ~~$85,000~~$75,000 and ~~$90,000~~$80,000 as of June 30, ~~2021~~2022 and December 31, ~~2020,~~2021, respectively.

In September 2020, the Company entered into a license and supply agreements with Jeil Pharma (the "Jeil Pharma Agreements"), for the rights to commercialize ~~Triferic~~TRIFERIC® (dialysate) (ferric pyrophosphate citrate) in South Korea. Under the terms of the Jeil Pharma Agreements, Jeil Pharma will be the exclusive development and commercialization partner for Triferic (dialysate) in South Korea, and the Company will supply the product to Jeil Pharma. In consideration for the license, the Company received an upfront fee of $0.2 ~~million,~~million. In May 2022, Jeil Pharma obtained regulatory approval in South Korea and ~~will be eligible for milestone payments and royalties on net sales. A Joint Alliance Committee, comprised of members from~~paid the Company ~~and Jeil Pharma, will guide~~$0.2 million in consideration of reaching the ~~development and execution for Triferic (dialysate) in South Korea. Jeil Pharma will be responsible for all clinical and regulatory approval, as well as commercialization activities.~~milestone. The upfront fee ~~was~~and milestone payments were recorded as deferred revenue and isare being recognized as revenue based on the agreement term. The Company recognized revenue of $2,500 and ~~NaN~~$7,800 for the three ~~months ended June 30, 2021~~ and ~~2020, respectively, and $5,000 and NaN for the~~ six months ended June 30, ~~2021~~2022, respectively, and ~~2020,~~$2,500 and $5,000 for the three and six months ended June 30, 2021, respectively. Deferred revenue related to the Jeil Pharma Agreement totaled approximately $0.4 million and $0.2 million as of June 30, ~~2021~~2022 and December 31, ~~2020.~~2021 respectively.

In June 2021, the Company entered into license and supply agreements with Drogsan Pharma (the "Drogsan Agreements"), for the rights to commercialize ~~Triferic~~TRIFERIC® (dialysate) and ~~Triferic AVNU in Turkey. Under the terms of the Drogsan Agreements, Drogsan Pharma will be the exclusive commercialization partner for Triferic (dialysate) and Triferic~~TRIFERIC® AVNU in Turkey. In consideration for the license, the Company ~~is due to receive~~received an upfront fee of $0.2 million, and will be eligible for milestone payment and royalties on net sales. A Joint Alliance Committee, comprised of members from the Company and Drogsan Pharma, will guide the execution for Triferic (dialysate) and Triferic AVNU in Turkey. Drogsan Pharma will be responsible for all regulatory approval and commercialization activities, and the Company will supply the product to Drogsan Pharma for Turkey.$0.15 million. The upfront fee ~~will be~~was recorded as deferred revenue and will be recognized as revenue based on the agreement term.

~~10. Stockholders’ Equity~~

~~Preferred Stock~~

As The Company recognized revenue of $3,750 and $7,500 for the three and six months ended June 30, 2022 and 2021, respectively. Deferred revenue related to the Drogsan Agreements totaled approximately $0.14 million as of each of June 30, ~~2021~~2022 and December 31, ~~2020, there were 2,000,000 shares of preferred stock, $0.0001 par value per share, authorized and 0 shares of preferred stock issued or outstanding.~~

~~Common Stock~~

As of June 30, 2021 and December 31, 2020, there were 170,000,000 shares of common stock, $0.0001 par value per share, authorized and 93,811,381 and 93,573,165 shares issued and outstanding, respectively.

~~Controlled Equity Offering (or "At the Market" Offering)~~

On March 22, 2019, the Company entered into a sales agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), pursuant to which the Company may offer and sell from time to time shares of the Company’s common stock through the Agent. The offering and sale of up to $40.0 million of the shares has been registered under the Securities Act of 1933, as amended (the "Securities Act"), pursuant to the Company’s registration statement on Form S-3 (File No. 333-227363), which was originally filed with the SEC on September 14, 2018 and declared effective by the SEC on October 1, 2018, the base prospectus contained within the registration statement, and a prospectus supplement that was filed with the SEC on March 22, 2019.

Sales of the shares, if any, pursuant to the Sales Agreement, may be made in sales deemed to be an “at the market" offering as defined in Rule 415(a) of the Securities Act, including sales made directly through the Nasdaq Global Market or on any other existing trading market for the Company’s common stock. The Company intends to use the proceeds from the offering for working capital and other general corporate purposes. The Company may suspend or terminate the Sales Agreement at any time.

2021.

1513

ROCKWELL MEDICAL, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

~~During~~10. Stockholders’ Equity

Reverse Stock Split

On May 9, 2022, the ~~three~~stockholders of the Company authorized our Board of Directors to effect a reverse stock split of all outstanding shares of common stock. The Board of Directors subsequently approved the implementation of a reverse stock split as a ratio of one-for-eleven shares, which became effective on May 13, 2022. The Company’s outstanding stock options were also adjusted to reflect the one-for-eleven reverse stock split of the Company’s common stock. Outstanding stock options were proportionately reduced and ~~six months ended~~the respective exercise prices, if applicable, were proportionately increased.

Preferred Stock

On April 6, 2022, the Company and DaVita entered into the SPA, which provided for the issuance by the Company of up to $15 million of preferred stock to DaVita. On April 6, 2022, the Company issued 7,500 shares of Series X Preferred Stock for gross proceeds of $7.5 million. On June 2, 2022, the Company met the conditions for the Second Tranche through a Registered Direct and Private Placement Offering by raising $15 million in additional capital. As a result, on June 16, 2022 the Company issued an additional 7,500 shares of the Series X Preferred Stock to DaVita for gross proceeds of $7.5 million.

The Series X Preferred Stock was issued for a price of $1,000 per share (the "Face Amount"), subject to accretion at a rate of 1% per annum, compounded annually. If the Company’s common stock trades above $22.00 for a period of 30 calendar days, the accretion will thereafter cease.

The Series X Convertible Preferred Stock is convertible to common stock at rate equal to the Face Amount, divided by a conversion price of $11.00 per share (subject to adjustment for future stock splits, reverse stock splits and similar recapitalization events). As a result, each share of Series X Preferred Stock will initially convert into approximately 91 shares of common stock. DaVita’s right to convert to common stock is subject to a beneficial ownership limitation, which is initially set at 9.9% of the outstanding common stock, which limitation may be reset (not to exceed 19.9%) at DaVita’s option and upon providing prior written notice to the Company. In addition, any debt financing is limited by the terms of our Securities Purchase Agreement with DaVita. Specifically, until DaVita owns less than 50% of its investment, the Company may only incur additional debt in the form of a purchase money loan, a working capital line of up to $5 million or to refinance existing debt, unless DaVita consents.

Additionally, the Series X Preferred Stock has a deemed liquidation event and redemption clause which could be triggered if the sale of all or substantially all of the Company's assets relating to the Company's dialysis concentrates business line. Since the Series X Preferred Stock may be redeemed if certain assets are sold at the option of the holder, but is not mandatorily redeemable, the preferred stock has been classified as permanent equity and initially recognized at fair value of $15 million (the proceeds on the date of issuance) less issuance costs of $0.1 million, resulting in an initial value of $14.9 million. The Company will assess at each reporting period whether conditions have changed to now meet the mandatorily redemptive definition which could trigger liability classification.

As of June 30, 2022 and December 31, 2021, there were 2,000,000 shares of preferred stock, $0.0001 par value per share, authorized and 15,000 and nil shares of preferred stock issued and outstanding, respectively.

Common Stock

As of June 30, 2022 and December 31, 2021, there were 170,000,000 shares of common stock, $0.0001 par value per share, authorized and 9,407,296 and 8,544,225 shares issued and outstanding, respectively.

Controlled Equity Offering

On April 8, 2022, the Company entered into the Sales Agreement with Cantor Fitzgerald & Co. as Agent, pursuant to which the Company may offer and sell from time to time up to $12,200,000 of shares of Company’s common stock through the Agent. The offering and sale of such shares has been registered under the Securities Act of 1933, as amended, pursuant to the Company’s Registration Statement on Form S-3 (File No. 333-259923) (the “Registration Statement”), which was originally filed with the SEC on September 30, 2021 and declared effective by the SEC on October 8, 2021, the base prospectus contained within the Registration Statement, and a prospectus supplement that was filed with the SEC on April 8, 2022.

In May 2022, the Company ~~has not~~ sold 7,500 shares of its common stock pursuant to the Sales ~~Agreement. Approximately $32.3 million remains available~~Agreement for gross proceeds of $15,135, at a weighted average selling price of approximately $2.02. The Company paid $378 in commissions and offering fees related to the sale of shares of common stock.

Under the RD Purchase Agreement and the PIPE Purchase Agreement discussed below, the Company has agreed not to make any sales under ~~this facility.~~any at-the-market offering facility, including pursuant to the Sales Agreement, until at least January 1, 2023 (or until such later time when the Company is permitted to make additional sales under Instruction I.B.6 to Form S-3).

Registered Direct Offering

On May 30, 2022, the Company entered into the RD Purchase Agreement with the Purchaser named therein, pursuant to which the Company agreed to issue and sell, in a registered direct offering (the “Offering”), 844,613 shares of its common stock at price of $1.39 per share, and pre-funded warrants to purchase up to an aggregate of 7,788,480 shares of common stock (the “Pre-Funded Warrants” and the shares of common stock underlying the Pre-Funded Warrants, the “Warrant Shares”). The purchase price of each Pre-Funded Warrant is equal to the price at which a share of common stock was sold to the public in the Offering, minus $0.0001, and the exercise price of each Pre-Funded Warrant is $0.0001 per share.

A holder (together with its affiliates) may not exercise any portion of the Pre-Funded Warrants to the extent the holder would own more than 9.99% of the Company’s outstanding common stock immediately after exercise, as such percentage ownership is determined in accordance with the terms of the Pre-Funded Warrant. The RD Purchase Agreement contains customary representations and warranties and agreements of the Company and the Purchaser and customary indemnification rights and obligations of the parties.

Private Placement

Also on May 30, 2022, concurrently with the Offering, the Company entered into the PIPE Purchase Agreement relating to the offering and sale (the “Private Placement”) of warrants to purchase up to a total of 9,900,990 shares of common stock and pre-funded warrants to purchase up to a total of 1,267,897 shares of common stock (the “PIPE Warrants”). Each warrant was sold at a price of $0.125 per underlying warrant share and is exercisable at an exercise price of $1.39 per share. The purchase price of each Pre-Funded Warrant was equal to the price at which a share of common stock was sold to the public in the Offering, minus $0.0001, and the exercise price of each prefunded warrant is $0.0001 per share.

In connection with the Private Placement, the Company entered into a Registration Rights Agreement with the Purchaser, dated as of June 2, 2022 (the “RRA”). Pursuant to the RRA, the Company was required to prepare and file a registration statement with the SEC no later than July 1, 2022, and to use its reasonable best efforts to have the registration statement declared effective as promptly as possible, subject to certain specified penalties if timely effectiveness is not achieved. The Company filed a registration statement on June 22, 2022 which became effective on July 5, 2022.

The Offering and the Private Placement closed on June 2, 2022. The net proceeds to the Company from the Offering and the Private Placement were approximately $14.9 million, after deducting fees and expenses. Subject to certain ownership limitations, the PIPE Warrants are exercisable upon issuance.

The Company has accounted for the common stock related to the Offering and Private Placement as equity on the accompanying consolidated balance sheets as of June 30, 2022. The amount allocated to common stock was $2.0 million. This allocation is ~~not required~~equal to ~~sell any shares at any time during~~ the ~~term~~total proceeds of $15.0 million less the amount allocated to Warrants of $12.9 million and is also net of the ~~facility.~~direct and incremental costs associated with the Offering and Private Placement of $0.1 million. The ~~Company's ability~~Black-Scholes pricing model was used to ~~sell common stock under~~calculate the ~~facility may be limited by several factors including, among other things,~~value of Warrants relating to the ~~trading volume of its common stock~~Offering and ~~certain black-out periods that the Company may impose upon the facility, among other things.~~Private Placement.

ROCKWELL MEDICAL, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

11. Stock-Based Compensation

The Company recognized total stock-based compensation expense during the three and six months ended June 30, ~~2021~~2022 and ~~2020~~2021 as follows (table in thousands):


		Three Months Ended June 30,				Six Months Ended June 30,					Three Months Ended June 30,				Six Months Ended June 30,
		2021		2020		2021		2020			2022		2021		2022		2021
Service-based awards:	Service-based awards:									Service-based awards:

Restricted stock units	Restricted stock units	$	78	$	(4)	$	182	$	234	Restricted stock units	$	26	$	78	$	37	$	182
Stock option awards	Stock option awards	344		336		735		776		Stock option awards	72		344		272		735
		422		332		917		1,010			98		422		309		917
Performance-based awards:	Performance-based awards:									Performance-based awards:
Restricted stock awards	Restricted stock awards	0		0		(390)		0		Restricted stock awards	—		—		(391)		(390)
Restricted stock units		0		(1,197)		0		(1,025)

Stock option awards	Stock option awards	11		(596)		(330)		(511)		Stock option awards	—		11		—		(330)
		11		(1,793)		(720)		(1,536)			—		11		(391)		(720)
Total	Total	$	433	$	(1,461)	$	197	$	(526)	Total	$	98	$	433	$	(82)	$	197

Performance Based Restricted Stock

A summary of the Company’s restricted stock awards during the six months ended June 30, 2022 is as follows:


	Number of Shares	Weighted Average Grant-Date Fair Value
Unvested at January 1, 2022	7,118	$	62.70
Forfeited	(6,227)	$	62.70
Unvested at June 30, 2022	891	$	62.70

A summary of the Company’s restricted stock awards during the six months ended June 30, 2021 is as follows:

Number of Shares Weighted Average
Grant-Date
Fair Value
Unvested at January 1, 2021 146,800 $ 5.70
Forfeited (68,500) $ 5.70
Unvested at June 30, 2021 78,300 $ 5.70

~~A summary of the Company’s restricted stock awards during the six months ended June 30, 2020 is as follows:~~

Number of Shares Weighted Average
Grant-Date
Fair Value
Unvested at January 1, 2020 146,800 $ 5.70
Unvested at June 30, 2020 146,800 $ 5.70


	Number of Shares	Weighted Average Grant-Date Fair Value
Unvested at January 1, 2021	13,345	$	62.70
Forfeited	(6,227)	$	62.70
Unvested at June 30, 2021	7,118	$	62.70

The fair value of restricted stock awards are measured based on their fair value on the date of grant and amortized over the vesting period of 20 months. As of June 30, ~~2021,~~2022, unvested restricted stock awards of ~~78,300~~891 were related to performance-based awards. The forfeited performance-based restricted stock awards of ~~68,500~~6,227 was due to the resignation of the Company's Chief Development Officer on March 25, 2022. These forfeited awards reduced stock-based compensation expense by $0.4 million. As of June 30, 2021, unvested restricted stock awards of 7,118 were related to performance-based awards. The forfeited performance-based restricted stock awards of 6,227 was due to the termination of the Company's former Chief Science Officer on January 19, 2021. These forfeited awards reduced stock-based compensation expense by $0.4 million.

1615

ROCKWELL MEDICAL, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Service-Based Restricted Stock Units

A summary of the Company’s service-based restricted stock units during the six months ended June 30, ~~2021~~2022 is as follows:


		Number of Shares	Weighted Average Grant-Date Fair Value			Number of Shares	Weighted Average Grant-Date Fair Value
Unvested at January 1, 2021		265,494	$	2.60
Unvested at January 1, 2022					Unvested at January 1, 2022	29,289	$	12.87
Granted	Granted	310,050	0.90		Granted	125,000	1.47
Vested	Vested	(221,474)	2.38		Vested	(23,515)	11.33
Forfeited	Forfeited	(11,466)	4.81		Forfeited	(5,774)	19.00
Unvested at June 30, 2021		342,604	$	1.17
Unvested at June 30, 2022					Unvested at June 30, 2022	125,000	$	1.47

A summary of the Company’s service-based restricted stock units during the six months ended June 30, ~~2020~~2021 is as follows:


		Number of Shares	Weighted Average Grant-Date Fair Value			Number of Shares	Weighted Average Grant-Date Fair Value
Unvested at January 1, 2020		463,786	$	4.26
Unvested at January 1, 2021					Unvested at January 1, 2021	24,136	$	28.60
Granted	Granted	188,904	2.09		Granted	28,186	9.90
Vested	Vested	(104,168)	4.66		Vested	(1,042)	52.91
Forfeited	Forfeited	(128,460)	4.30		Forfeited	(20,134)	26.18

Unvested at June 30, 2020		420,062	$	3.27
Unvested at June 30, 2021					Unvested at June 30, 2021	31,146	$	12.87

The fair value of service based restricted stock units are measured based on their fair value on the date of grant and amortized over the vesting period. The vesting periods range from 1 to 3 years. Stock-based compensation expense of $25,554 and $37,417 was recognized for the three and six months ended June 30, 2022, respectively. Stock-based compensation expense of $0.1 million and $0.2 million was recognized for the three and six months ended June 30, 2021, respectively. ~~Stock-based compensation expense of NaN and $0.2 million was recognized for the three and six months ended June 30, 2020, respectively.~~ As of June 30, ~~2021,~~2022, the unrecognized stock-based compensation expense was ~~$0.3~~$0.1 million, which is expected to be recognized over an estimated weighted average remaining term of less than 1 year.

~~Performance-Based Restricted~~Service-Based Stock ~~Units~~Options

~~As of June 30, 2021, there were 0 outstanding performance-based restricted stock units.~~

~~A summary~~The fair value of the ~~Company’s performance-based restricted~~service-based stock ~~units during~~options granted for the six months ended June 30, ~~2020 is as follows:~~2022 were based on the following assumptions:

Number of Shares Weighted Average
Grant-Date
Fair Value
Unvested at January 1, 2020 988,958 $ 4.48
Forfeited (905,625) 4.61
Unvested at June 30, 2020 83,333 $ 3.09

~~Service-Based Stock Options~~


			June 30, 2022
Exercise price			$4.12
Expected stock price volatility			76.2%
Risk-free interest rate			1.98%
Term (years)			6.5

1716

ROCKWELL MEDICAL, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

~~The fair value~~A summary of the Company’s service-based stock ~~options granted~~option activity for the six months ended June 30, ~~2021 were based on the following assumptions:~~2022 is as follows:


			June 30, 2021
~~Exercise price~~			~~$0.90 - $0.94~~
~~Expected stock price volatility~~			~~75.8% - 77.7%~~
~~Risk-free interest rate~~			~~0.47% - 1.06%~~
~~Term (years)~~			~~5.5 - 6~~


	Shares Underlying Options	Weighted Average Exercise Price		Weighted Average Remaining Contractual Term	Aggregate Intrinsic Value
Outstanding at January 1, 2022	528,591	$	32.01	7.5	$	—
Granted	909	4.07		9.5	—

Forfeited	(24,488)	15.00		—	—
Expired	(81,695)	83.32		—	—
Outstanding at June 30, 2022	423,317	$	23.03	7.8	$	—

Exercisable at June 30, 2022	227,412	$	31.19	7.2	$	—

A summary of the Company’s service-based stock option activity for the six months ended June 30, 2021 is as follows:

Shares
Underlying
Options Weighted
Average Exercise
Price Weighted
Average
Remaining
Contractual
Term Aggregate
Intrinsic
Value
Outstanding at January 1, 2021 5,717,956 $ 4.55 6.6 $ 0
Granted 1,522,162 0.96 6.0 —
Forfeited (277,764) 2.52 — —
Expired (1,266,553) 7.35 — —
Outstanding at June 30, 2021 5,695,801 $ 3.07 7.8 $ 5,000
Exercisable at June 30, 2021 2,387,440 $ 5.25 5.8 $ 0

~~A summary of the Company’s service-based stock option activity for the six months ended June 30, 2020 is as follows:~~


		Shares Underlying Options	Weighted Average Exercise Price		Weighted Average Remaining Contractual Term	Aggregate Intrinsic Value			Shares Underlying Options	Weighted Average Exercise Price		Weighted Average Remaining Contractual Term	Aggregate Intrinsic Value
Outstanding at January 1, 2020		8,210,024	$	7.06	5.1	$	107,000
Outstanding at January 1, 2021								Outstanding at January 1, 2021	519,814	$	50.05	6.6	$	—
Granted	Granted	1,610,344	2.24		5.9	—		Granted	138,378	10.56		6.0	—
Forfeited	Forfeited	(211,471)	4.41		—	—		Forfeited	(25,251)	27.72		—	—
Expired	Expired	(3,983,335)	8.30		—	—		Expired	(115,141)	80.85		—	—
Outstanding at June 30, 2020		5,625,562	$	4.90	6.7	$	1,000
Outstanding at June 30, 2021								Outstanding at June 30, 2021	517,800	$	33.77	7.8	$	5,000

Exercisable at June 30, 2020		2,809,954	$	7.09	4.3	$	0
Exercisable at June 30, 2021								Exercisable at June 30, 2021	217,040	$	57.75	5.8	$	—

The aggregate intrinsic value in the table above is calculated as the difference between the closing price of the Company's common stock and the exercise price of the stock options that had strike prices below the closing price.

During the six months ended June 30, ~~2021,~~2022, the Company granted stock options to purchase up to ~~1,522,162~~909 shares of common stock to certain employees. During the six months ended June 30, ~~2021, 277,764~~2022, 24,488 shares were forfeited and ~~1,266,553~~81,695 shares expired. Forfeitures are recorded in the period of occurrence; compensation expense is adjusted accordingly.

Stock-based compensation expense recognized for service-based stock options was $0.1 million and $0.3 million for the three and six months ended June 30, 2022, respectively. Stock-based compensation expense recognized for service-based stock options was $0.3 million and $0.7 million for the three and six months ended June 30, 2021, respectively. ~~Stock-based compensation expense recognized for service-based stock options was $0.3 million and $0.8 million for the three and six months ended June 30, 2020, respectively.~~ As of June 30, ~~2021,~~2022, total stock-based compensation expense related to unvested options not yet recognized totaled approximately ~~$2.0~~$0.7 million, which is expected to be recognized over an estimated weighted average remaining term of ~~3.0~~3.3 years.

~~Performance-Based Stock Options~~

ROCKWELL MEDICAL, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

~~A summary of the performance-based stock options for the six months ended June 30, 2021 is as follows:~~

Number of Shares Weighted Average
Exercise
Price
Outstanding at January 1, 2021 750,000 $ 2.20
Expired (375,000) 2.20
Outstanding at June 30, 2021 375,000 $ 2.20
Exercisable at June 30, 2021 0 $ 0

~~A summary of the performance-based stock options for the six months ended June 30, 2020 is as follows:~~

Number of Shares Weighted Average
Exercise
Price
Outstanding at January 1, 2020 388,125 $ 4.70
Granted 600,000 $ 2.45
Forfeited (388,125) $ 4.70
Outstanding at June 30, 2020 600,000 $ 2.45
Exercisable at June 30, 2020 0 $ 0

Stock-based compensation expense recognized for performance-based stock options was NaN and $(0.3) million for the three and six months ended June 30, 2021, respectively. Stock-based compensation expense recognized for performance-based stock options was $(0.6) million and $(0.5) million for the three and six months ended June 30, 2020, respectively. The reduction in stock-based compensation expense was due to the performance criteria of certain performance-based options granted to officers of the Company becoming non-probable as of March 31, 2021. The Company will continue to assess the probability of the performance criteria until such time the criteria becomes probable and the performance-based stock option vests or continues to be non-probable and the performance-based stock option expires. As of June 30, 2021, there was 0 unrecognized stock-based compensation expense related to unvested performance-based stock options.

12. Licensing Agreements

Product License Agreements

The Company is a party to a Licensing Agreement ~~with~~between the Company and Charak, LLC ("Charak") dated January 7, 2002 (the "2002 Agreement") that grants the Company exclusive worldwide rights to certain patents and information related to our ~~Triferic®~~TRIFERIC® product. On October 7, 2018, the Company entered into a Master Services and IP Agreement (the “Charak MSA”) with Charak and Dr. Ajay Gupta, a former Officer of the Company. Pursuant to the MSA, the parties entered into 3 additional agreements described below related to the license of certain soluble ferric pyrophosphate (“SFP”) intellectual property owned by Charak. The Charak MSA provided for a payment of $1.0 million to Dr. Gupta, payable in 4 quarterly installments of $250,000 each on October 15, 2018, January 15, 2019, April 15, 2019 and July 15, 2019, and reimbursement for certain legal fees incurred in connection with the Charak MSA. The Company paid all four of the quarterly installments totaling $1.0 million and accrued $0.1 million for the reimbursement of certain legal expenses during the year ended December 31, 2019. As of December 31, 2020, the Company had fulfilled its reimbursement obligation of certain legal expenses. As of June 30, ~~2021,~~2022, the Company has accrued ~~$0.2 million~~$77,900 relating to certain IP reimbursement expenses and certain sublicense royalty fees and is included within accrued liabilities on the condensed consolidated balance sheet.

Pursuant to the Charak MSA, the aforementioned parties entered into an Amendment, dated as of October 7, 2018 (the “Charak Amendment”), to the 2002 Agreement, under which Charak granted the Company an exclusive, worldwide, non-transferable license to commercialize SFP for the treatment of patients with renal failure. The Charak Amendment amends the royalty payments due to Charak under the 2002 Agreement such that the Company is liable to pay Charak royalties on net sales

~~ROCKWELL MEDICAL, INC. AND SUBSIDIARIES~~

~~Notes to Condensed Consolidated Financial Statements~~

~~(Unaudited)~~

by the Company of products developed under the license, which includes the Company’s ~~Triferic®~~TRIFERIC® product, at a specified rate until December 31, 2021 and thereafter at a reduced rate from January 1, 2022 until February 1, 2034. Additionally, the Company shall pay Charak a percentage of any sublicense income during the term of the agreement, which amount shall not be less than a minimum specified percentage of net sales of the licensed products by the ~~sub-licensee~~sublicensee in jurisdictions where there exists a valid claim, on a country-by-country basis, and be no less than a lower rate of the net sales of the licensed products by the ~~sub-licensee~~sublicensee in jurisdictions where there exists no valid claim, on a country-by-country basis.

Also pursuant to the Charak MSA, the Company and Charak entered into a Commercialization and Technology License Agreement I.V. ~~Triferic® (now Triferic AVNU)~~TRIFERIC®, dated as of October 7, 2018 (the “IV Agreement”), under which Charak granted the Company an exclusive, ~~sub-licensable,~~sublicensable, royalty-bearing license to SFP for the purpose of commercializing certain intravenous-delivered products incorporating SFP for the treatment of iron disorders worldwide for a term that expires on the later of February 1, 2034 or upon the expiration or termination of a valid claim of a licensed patent. The Company is liable to pay Charak royalties on net sales by the Company of products developed under the license at a specified rate until December 31, 2021. From January 1, 2022 until February 1, 2034, the Company is liable to pay Charak a base royalty at a reduced rate on net sales and an additional royalty on net sales while there exists a valid claim of a licensed patent, on a country-by-country basis. The Company shall also pay to Charak a percentage of any sublicense income received during the term of the IV Agreement, which amount shall not be less than a minimum specified percentage of net sales of the licensed products by the ~~sub-licensee~~sublicensee in jurisdictions where there exists a valid claim, on a country-by-country basis, and not be less than a lower rate of the net sales of the licensed products by the ~~sub-licensee~~sublicensee in jurisdictions where there exists no valid claim, on a country-by-country basis.

Also pursuant to the Charak MSA, the Company and Charak entered into a Technology License Agreement TPN ~~Triferic®~~TRIFERIC®, dated as of October 7, 2018 (the “TPN Agreement”), pursuant to which Charak granted the Company an exclusive, sublicensable, royalty-bearing license to SFP for the purpose of commercializing worldwide certain ~~parenteral nutritional ("TPN”)~~TPN products incorporating SFP. The license grant under the TPN Agreement continues for a term that expires on the later of February 1, 2034 or upon the expiration or termination of a valid claim of a licensed patent. During the term of the TPN Agreement, the Company is liable to pay Charak a base royalty on net sales and an additional royalty on net sales while there exists a valid claim of a licensed patent, on a country-by-country basis. The Company shall also pay to Charak a percentage of any sublicense income received during the term of the TPN Agreement, which amount shall not be less than a minimum royalty on net sales of the licensed products by the ~~sub-licensee~~sublicensee in jurisdictions where there exists a valid claim, on a country-by-country basis, and not be less than a lower rate of the net sales of the licensed products by the ~~sub-licensee~~sublicensee in jurisdictions where there exists no valid claim, on a country-by-country basis.

The potential milestone payments are not yet considered probable, and no milestone payments have been accrued at June 30, 2022.

ROCKWELL MEDICAL, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

13. Leases

~~The Company~~Rockwell leases its production facilities and administrative offices as well as certain equipment used in ~~our~~its operations including leases on transportation equipment used in the delivery of its products. The lease terms range from monthly to ~~five~~six years. ~~The Company~~Rockwell occupies a 51,000 square foot facility and a 17,500 square foot facility in Wixom, Michigan under a lease expiring in August 2024. ~~The Company~~Rockwell also occupies two other manufacturing facilities, a 51,000 square foot facility in Grapevine, Texas under a lease expiring in December 2025, and a 57,000 square foot facility in Greer, South Carolina under a lease expiring February 2023. In addition, ~~the Company occupies~~Rockwell occupied 4,100 square feet of office space in Hackensack, New Jersey under a lease expiring on ~~July 1,~~October 31, 2024. This lease ~~is currently being offered for sublease.~~was subleased on December 15, 2021 with an expiration date of October 31, 2024.

At June 30, ~~2021,~~2022, the Company had operating and finance lease liabilities of ~~$6.2~~$6.9 million and right-of-use assets of ~~$6.1~~$6.7 million, which are included in the consolidated balance sheet.

At December 31, ~~2020,~~2021, the Company had operating lease liabilities of ~~$3.0~~$7.9 million and right-of-use assets of ~~$2.9~~$7.7 million, which are included in the consolidated balance sheet.

The following summarizes quantitative information about the Company’s operating leases (table in thousands):


	Three Months Ended June 30, 2022			Three Months Ended June 30, 2021			Six Months Ended June 30, 2022			Six Months Ended June 30, 2021
Operating leases
Operating lease cost	$	431		$	432		$	880		$	851
Variable lease cost	92			90			187			192
Operating lease expense	523			522			1,067			1,043
Finance leases
Amortization of right-of-use assets	141			67			282			112
Interest on lease obligations	45			20			92			33
Finance lease expense	186			87			374			145
Short-term lease rent expense	4			4			8			8
Total rent expense	$	713		$	613		$	1,449		$	1,196

Other information
Operating cash flows from operating leases	$	447		$	428		$	911		$	853
Operating cash flows from finance leases	$	45		$	21		$	92		$	34
Financing cash flows from finance leases	$	119		$	56		$	237		$	93
Right of use assets exchanged for operating lease liabilities	$	—		$	1,476		$	—		$	3,371
Right of use assets exchanged for finance lease liabilities	$	—		$	316		$	—		$	777
Weighted-average remaining lease term – operating leases	3.2			3.5			3.2			3.5
Weighted-average remaining lease term – finance leases	4.9			5.5			4.9			5.5
Weighted-average discount rate – operating leases	6.3		%	6.2		%	6.3		%	6.2		%
Weighted-average discount rate – finance leases	6.4		%	5.5		%	6.4		%	5.5		%

Future minimum rental payments under operating lease agreements are as follows (in thousands):


	Operating		Finance
Year ending December 31, 2022 (remaining)	$	861	$	331
Year ending December 31, 2023	1,456		669
Year ending December 31, 2024	1,114		672
Year ending December 31, 2025	637		676
Year ending December 31, 2026	260		666
Remaining future payments	120		310
Total	$	4,448	$	3,324
Less present value discount	(420)		(470)
Operating and finance lease liabilities	$	4,028	$	2,854

ROCKWELL MEDICAL, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Three Months Ended June 30, 2021 Three Months Ended June 30, 2020 Six Months Ended June 30, 2021 Six Months Ended June 30, 2020
Operating leases
Operating lease cost $ 432 $ 403 $ 851 $ 846
Variable lease cost 90 123 192 312
Operating lease expense 522 526 1,043 1,158
Finance leases
Amortization of right-of-use assets 67 0 112 0
Interest on lease obligations 20 0 33 0
Finance lease expense 87 0 145 0
Short-term lease rent expense 4 4 8 8
Total rent expense $ 613 $ 530 $ 1,196 $ 1,166
Other information
Operating cash flows from operating leases $ 428 $ 410 $ 853 $ 855
Operating cash flows from finance leases $ 21 $ 0 $ 34 $ 0
Financing cash flows from finance leases $ 56 $ 0 $ 93 $ 0
Right of use assets exchanged for operating lease liabilities $ 1,476 $ 0 $ 3,371 $ 0
Right of use assets exchanged for finance lease liabilities $ 316 $ 0 $ 777 $ 0
Weighted-average remaining lease term – operating leases 3.5 2.4 3.5 2.4
Weighted-average remaining lease term – finance leases 5.5 0.0 5.5 0
Weighted-average discount rate – operating leases 6.2 % 6.8 % 6.2 % 6.8 %
Weighted-average discount rate – finance leases 5.5 % 0 % 5.5 % 0 %

~~Future minimum rental payments under operating lease agreements are as follows (in thousands):~~

Operating Finance
Year ending December 31, 2021 (remaining) $ 865 $ 148
Year ending December 31, 2022 1,603 300
Year ending December 31, 2023 1,285 305
Year ending December 31, 2024 930 305
Year ending December 31, 2025 468 305
Remaining future payments 97 319
Total $ 5,248 $ 1,682
Less present value discount (522) (228)
Operating and finance lease liabilities $ 4,726 $ 1,454

14. ~~Commitments and Contingencies~~

~~Litigation~~

~~SEC Investigation~~

As a follow up to certain prior inquiries, the Company received a subpoena from the SEC during the Company’s quarter ended September 30, 2018 requesting, among other things, certain information and documents relating to the status of the Company’s request to the Centers for Medicare & Medicaid Services (the "CMS") for separate reimbursement

~~ROCKWELL MEDICAL, INC. AND SUBSIDIARIES~~

~~Notes to Condensed Consolidated Financial Statements~~

~~(Unaudited)~~

status for Triferic (dialysate), the Company’s reserving methodology for expiring Triferic inventory, and the basis for the Board’s termination of the former Chief Executive Officer, Robert Chioini, and former Chief Financial Officer, Thomas Klema, in 2018. The Company is cooperating with the SEC and is responding to the SEC’s requests for documents and information.

~~15.~~ Loan and Security Agreement

InOn March 16, 2020, ~~Rockwell Medical, Inc.~~the Company and Rockwell Transportation, Inc., as Borrowers, entered into a Loan and Security Agreement (the "Loan Agreement") with Innovatus Life Sciences Lending Fund I, LP ("Innovatus"), as collateral agent and the lenders party thereto, pursuant to which Innovatus, as a lender, agreed to make certain term loans to the Company in the aggregate principal amount of up to $35.0 million (the "Term Loans"). Funding of the first $22.5 million tranche was completed on March 16, 2020. The Company is no longer eligible to draw on a second tranche of $5.0 million or a third tranche of $7.5 million, which ~~was~~were tied to the achievement of certain milestones by a specific date. ~~The Company may be eligible to draw on a third tranche of $7.5 million upon the achievement of certain additional milestones, including the achievement of certain Triferic sales thresholds.~~ Net draw down proceeds were $21.2 million with closing costs of $1.3 million.

In connection with each funding of the Term Loans, the Company is required to issue to Innovatus a warrant (the “Warrants”) to purchase a number of shares of the Company’s common stock equal to 3.5% of the principal amount of the relevant Term Loan funded divided by the exercise price, which will be based on the lower of (i) the volume weighted average closing price of the Company’s stock for the 5-trading day period ending on the last trading day immediately preceding the execution of the Loan Agreement or (ii) the closing price on the last trading day immediately preceding the execution of the Loan Agreement (or for the second and third tranches only at the lower of (i) $18.15 per share or (ii) the volume weighted average closing price of the Company’s stock for the 5-trading day period ending on the last trading day immediately preceding the relevant Term Loan funding). The Warrants may be exercised on a cashless basis and are immediately exercisable through the seventh anniversary of the applicable funding date. The number of shares of common stock for which each Warrant is exercisable and the associated exercise price are subject to certain proportional adjustments as set forth in such Warrant. In connection with the first tranche of the Term Loans, the Company issued a Warrant to Innovatus, exercisable for an aggregate of 43,388 shares of the Company’s common stock at an exercise price of $18.15 per share. The Company evaluated the warrant under ASC 470, Debt, and recognized an additional debt discount of approximately $0.5 million based on the relative fair value of the base instruments and warrants. The Company calculated the fair value of the warrant using the Black-Scholes model.

The Company is entitled to make interest-only payments for thirty months, or up to thirty-six months if certain conditions are met. The Term Loans will mature on March 16, 2025, and will bear interest at the greater of (i) Prime Rate (as defined in the Loan Agreement) and (ii) 4.75%, plus 4.00% with an initial interest rate of 8.75% per annum and an effective interest rate of 10.9%. The Company has the option, under certain circumstances, to add 1.00% of such interest rate amount to the then outstanding principal balance in lieu of paying such amount in cash. For ~~each of~~ the three months ended June 30, 2022 and 2021, interest expense amounted to $0.4 million and $0.6 ~~million.~~million, respectively. For the six months ended June 30, ~~2021~~2022 and ~~2020,~~2021, interest expense amounted to ~~$1.2~~$0.8 million and ~~$0.6~~$1.2 million, respectively.

The Loan Agreement is secured by all assets of the Company and Rockwell Transportation, Inc. Proceeds are ~~being~~ used for working capital purposes. The Loan Agreement contains customary representations and warranties and covenants, subject to customary carve outs, and includes financial covenants related to liquidity and trailing twelve months sales of ~~Triferic,~~TRIFERIC®, with the latter beginning with the period ending December 31, 2020. The Company cannot assure you that we can maintain compliance with the covenants under our Loan Agreement, which may result in an event of default. The Company's ability to comply with these covenants may be adversely affected by events beyond its control. For example, the Loan Agreement contains certain financial covenants relating to sales and, as a result of the ongoing COVID-19 pandemic and its effect on the Company's sales activities, among other factors, the Company may not be able to satisfy such covenants in the future. If the Company is unable to comply with the covenants under the Loan Agreement, it would pursue all available cure options in order to regain compliance. ~~The Company previously failed to satisfy a revenue covenant for the period ended December 31, 2020 and then subsequently agreed to an appropriate remedy during the applicable cure period.~~ However, the Company may not be able to mutually agree with Innovatus on appropriate remedies to cure a future breach of a covenant, which could give rise to an event of default. If the Company is unable to avoid an event of default, any required repayments could have an adverse effect on its liquidity. As of June 30, 2021, the Company is in compliance with all the reporting and financial covenants. The financial statements for June 30, 2021 have been prepared with the assumption that the Company will be able to agree to an appropriate remedy during the applicable cure period for any future breaches of operating covenants. Based on the foregoing, the Company has classified amounts payable under the Loan Agreement as a current liability.~~If and when the Company reaches an agreement with Innovatus to avoid an event of default, the amounts payable under the Loan Agreement will be reevaluated for its classification and presentation.~~

In ~~connection with each funding of the Term Loans,~~September 2021, the Company ~~is required~~entered into an amendment to ~~issue~~the Loan Agreement in which the Company, in exchange for Innovatus lowering the sales covenants, agreed to ~~Innovatus a warrant (the “Warrants”) to purchase a number of shares of the Company’s common stock equal to 3.5% of the~~(i) prepay an aggregate principal amount of $7,500,000 in 10 installments commencing on December 1, 2021; (ii) pay an additional prepayment premium of 5% on prepaid amounts if the ~~relevant~~Company elects to prepay all outstanding Term ~~Loan funded divided by~~Loans on or before September 24, 2023 and (iii) maintain minimum liquidity of no less than $5,000,000 if the ~~exercise price, which will be based on~~aggregate principal amount of Term Loans is greater than $15,000,000 pursuant to the ~~lower of (i) the volume weighted average closing price of the Company’s stock for the 5-trading day period ending on the last trading day immediately preceding the execution of~~liquidity covenant in the Loan Agreement or (ii) the closing price on the last trading day immediately preceding the execution of the Loan Agreement (or for the second and third tranches only at the lower of (i) $1.65 per share or (ii) the volume weighted average closing price of the Company’s stock for the 5-trading day period ending on the last trading day immediately preceding the relevant Term Loan funding). The Warrants may be exercised on a cashless basis and are immediately exercisable through the seventh anniversary of the applicable funding date. The number of shares of common stock for which each Warrant is exercisable and the associated exercise price are subject to certain proportional adjustments as set forth in such Warrant. In connection with the first tranche of the Term Loans, the Company issued a Warrant to Innovatus, exercisable for an aggregate of 477,273 shares of the Company’s common stock at an exercise price of $1.65 per share. The Company evaluated the warrant under ASC 470, Debt, and recognized an additional debt discount of approximately $0.5 million based on the relative fair value of the base instruments and warrants. The Company calculated the fair value of the warrant using the Black-Scholes model.Agreement.

~~ROCKWELL MEDICAL, INC. AND SUBSIDIARIES~~

~~Notes~~On March 31, 2022, the Collateral Agent and Lenders consented to ~~Condensed Consolidated Financial Statements~~

~~(Unaudited)~~

the delivery to Collateral Agent and Lenders of its annual audited financial statements for the fiscal year 2021 by April 15, 2022 as opposed to within 90 days of December 31, 2021, as required pursuant to Loan Agreement.

As of June 30, ~~2021,~~2022, the Company was in compliance with all covenants under the Loan Agreement.

As of June 30, 2022, the outstanding balance of the Term Loan was ~~$21.1~~$15.5 million, net of unamortized issuance costs and ~~unaccreted~~ discount of ~~$1.4~~$1.0 million.

The following table reflects the schedule of principal payments on the Term Loan as of June 30, ~~2021~~2022 (in thousands):


		Principal Payments			Principal Payments

2021		$	0
2022	2022	2,250		2022	$	2,500
2023	2023	9,000		2023	6,000
2024	2024	9,000		2024	6,000
2025	2025	2,250		2025	2,000
		$	22,500
					$	16,500

~~16. Subsequent Events~~

ROCKWELL MEDICAL, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Unaudited)

15. Insurance Financing Note Payable

On ~~July 3, 2021,~~June 2, 2022, the Company entered into a short-term note payable for ~~$2.0~~$1.5 million, bearing interest at ~~3.925%~~5.40% per annum to finance various insurance policies. Principal and interest payments related to this note ~~will begin~~began on July 3, ~~2021~~2022 and ~~are~~were paid on a straight-line amortization over ~~a 9-month period~~9 months with the final payment due on March 3, ~~2022.~~2023. As of June 30, 2022, the Company's insurance note payable balance was $1.5 million.

16. Subsequent Events

On July 14, 2022, 952,897 Pre-Funded Warrants to purchase common stock pursuant the SPA entered into on May 30, 2022 were exercised. The exercise price of each Pre-Funded Warrant is $0.0001 per share and resulted in gross proceeds of $95.29 (See Note 10 for more detail on the SPA).

On July 14, 2022, the Company filed a Registration Statement on Form S-3 under the Securities Act of 1933 to register the shares of common stock underlying the shares of Series X Preferred Stock issued to DaVita on April 6, 2022 and June 16, 2022. The Form S-3 was declared effective by the SEC on July 22, 2022 (See Note 10 for more detail).

On August 10, 2022, 315,000 Pre-Funded Warrants to purchase common stock pursuant the SPA entered into on May 30, 2022 were exercised. The exercise price of each Pre-Funded Warrant is $0.0001 per share and resulted in gross proceeds of $31.50 (See Note 10 for more detail on the SPA).

2321

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis should be read in conjunction with our condensed consolidated financial statements and related notes in “Item 1. Condensed Consolidated Financial Statements”. References in this report to "Rockwell," the “Company,” “we,” “our” and “us” are references to Rockwell Medical, Inc. and its subsidiaries.

Forward-Looking Statements

We make forward-looking statements in this report and may make such statements in future filings with the Securities and Exchange Commission, or SEC. We may also make forward-looking statements in our press releases or other public or shareholder communications. Our forward-looking statements are subject to risks and uncertainties and include information about our current expectations and possible or assumed future results of our operations. When we use words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “could,” “plan,” “potential,” “predict,” “forecast,” “project,” “intend,” or similar expressions, or make statements regarding our intent, belief, or current expectations, we are making forward-looking statements. Our forward looking statements also include, without limitation, statements about our liquidity and capital resources; our ~~plans and~~ ability to ~~successfully commercialize our products; our ability to successfully launch FDA-approved Triferic AVNU;~~continue as a going concern; our ability to develop ~~FPC~~Ferric Pyrophosphate Citrate ("FPC") for other indications; our ability to successfully execute on our business strategy and development of new indications; our ability to raise additional capital; our ability to renegotiate certain terms of our supply contracts; our ability to successfully implement certain cost containment and cost-cutting measures and statements regarding our anticipated future financial condition, operating results, cash flows and business plans.

While we believe ~~that~~ our forward-looking statements are reasonable, you should not place undue reliance on any such forward-looking statements, which are based on information available to us on the date of this report or, if made elsewhere, as of the date made. Because these forward-looking statements are based on estimates and assumptions that are subject to significant business, economic and competitive uncertainties, many of which are beyond our control or are subject to change, actual results could be materially different. Factors that might cause such a difference include, without limitation, the risks and uncertainties discussed in this report, “Item 1A — Risk Factors” in our Form 10-K for the year ended December 31, ~~2020~~2021 and from time to time in our other reports filed with the SEC, including in this Form 10-Q.

Other factors not currently anticipated may also materially and adversely affect our results of operations, cash flow and financial position. There can be no assurance ~~that~~ future results will meet expectations. Forward-looking statements speak only as of the date of this report and we expressly disclaim any intent to update or alter any statements whether as a result of new information, future events or otherwise, except as may be required by applicable law.

Overview

Rockwell Medical is a commercial healthcare company focused on providing life-sustaining products for patients suffering from blood disorders and ~~Recent Developments~~

diseases associated with the kidney. Rockwell is a ~~commercial-stage, biopharmaceutical company~~revenue-generating business and the second largest supplier of acid and bicarbonate concentrates for dialysis patients in the United States. Hemodialysis is the most common form of end-stage renal disease treatment and is usually performed at a freestanding outpatient dialysis center, at a hospital-based outpatient center, or at the patient’s home.

We manufacture our hemodialysis concentrates under cGMP regulations at our three facilities in Michigan, Texas, and South Carolina totaling approximately 175,000 square feet, from which we deliver these products to dialysis clinics throughout the United States with our own delivery fleet as well as third parties. We also manufacture mixers that are used by clinics in our Iowa facility. Rockwell has developed a core expertise in manufacturing and delivering hemodialysis concentrates, and has built a longstanding reputation for reliability, quality, and excellent customer service.

Rockwell commercializes Triferic in the United States, an FDA-approved treatment indicated for the replacement of iron to maintain hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease. Rockwell also has a number of partnerships with companies seeking to develop and commercialize Triferic outside the United States. Rockwell is working closely with these partners to progress these programs.

We have an emerging portfolio of drug development candidates we are pursuing. Rockwell is developing ~~and commercializing our~~a next-generation, proprietary parenteral iron technology platform, Ferric Pyrophosphate Citrate ~~("FPC"~~(“FPC”)~~, which we believe has the potential to lead to transformative treatments for iron deficiency in multiple disease states, that we believe could reduce healthcare costs and improve patients’ lives.~~. We ~~are also one of the two major suppliers of life-saving hemodialysis concentrate products to kidney dialysis clinics in the United States.~~

~~We have two novel, FDA approved therapies, Triferic and Triferic AVNU, which are the first two products developed from~~believe our FPC ~~platform. We are marketing both products to kidney dialysis centers for their patients receiving dialysis. In 2021, we intend to advance our FPC~~ platform ~~strategy outside of dialysis by starting a Phase 2 trial for the treatment of iron deficiency anemia in patients who are receiving long-term and or chronic intravenous~~(“IV”) medications for various therapeutic needs in the home infusion setting.. The trend toward providing medical care, including the delivery of medicines, at home make the home infusion market a rapidly growing area of healthcare. We believe that the home infusion setting is a natural path for expansion of our platform as many of the patients suffer from chronic diseases that are associated with iron deficiency and anemia. We are currently seeking additional FDA feedback and clarification regarding the clinical development plan for FPC in the home-infusion setting. Our expectations regarding the commencement of a Phase 2 trial in 2021 is based on the assumption that the FDA agrees with the development plan as we have proposed. In our R&D pipeline, we are also investigating FPC’s impact on iron deficiency in the treatment of hospitalized patients with acute heart failure, with the potential to begin another Phase 2 trial in these patients in 2022.

We are the second largest supplier of hemodialysis concentrates in the United States, with a reputation for excellent service, quality, and reliability. We believe that this reputation, which is based on over 25 years of service to the kidney

dialysis centers, combined with about $60 million in annual revenue, approximately 300 dedicated employees, expertise in manufacturing and logistics and the added expertise in pharmaceutical development and commercialization brought to the Company by recent additions to our management team, gives us a solid foundation on which to grow.

At Rockwell Medical, we are dedicated to replacing the currently inadequate standard of care for treatment of iron deficiency in acute and chronic disease by leveraging our proprietary FPC platform technology. We believe that our proprietary drug platform, FPC, is a next-generation parenteral iron therapeutic that has several advantages over other parenteral iron ~~therapies. Importantly, it provides~~therapies by immediately providing bioavailable iron ~~that is immediately bioavailable~~ for critical

body processes once it is administered. ~~It has been demonstrated~~Rockwell plans to ~~be safe~~move product candidates derived from this platform into the clinic to treat iron-deficiency anemia in the home infusion setting and ~~well-tolerated, with a safety profile similar to placebo.~~

Iron deficiency, which is often overlooked and undertreated in several illnesses because of the difficulty in treating them, can develop into a serious medical condition when left untreated. It is a common comorbidity in many disease states, such as end-stage kidney disease, chronic kidney disease,for acute heart ~~failure, cancer~~failure.

Together, with our dedicated employees and ~~multiple chronic gastrointestinal conditions. Iron deficiency impacts patients’ health~~deep expertise in ~~many ways, including anemia, organ dysfunction, slower recovery, diminished energy~~manufacturing and ~~reduced quality of life.~~

~~Strategy Evolution~~logistics and ~~Overview~~

Rockwell Medical has evolved its strategy over the past year to develop into a more medically-, scientifically- and data-driven company. We believe future clinical, regulatory and commercial success require the right people with the right experience to navigate us to the right data. There has been an evolution of both our management and board, providing us with greater relevant experience. In particular, we have added board members and employees with significant medical and commercial experience in iron deficiency anemia and the dialysis sector, drugpharmaceutical development and commercialization, ~~small-cap public company finance and management and clinical nurse educator patient support.~~ We believe ~~these changes~~Rockwell is well-positioned to realize sustainable business growth and support ~~an improved execution of~~ our ~~strategy~~mission to ~~generate data that will support future commercial growth, fair reimbursement~~provide life-sustaining products for patients suffering from blood disorders and ~~regulatory approvals.~~diseases associated with the kidney.

~~Our~~Strategy Overview and Portfolio Evolution

Rockwell’s strategy is to accelerate ~~Rockwell’s~~the Company’s growth by creating and developing pharmaceutical products based on our FPC technology for disease states where patients can benefit the most from an effective treatment for iron deficiency or iron deficiency anemia, while concurrently refining our concentrates dialysis business to drive incremental growth and efficiencies. We plan to leverage and build on the foundation provided by our current dialysis business serving kidney dialysis centers by developing a pipeline of additional potential drug therapies in multiple disease states outside of nephrology. ~~We have preliminarily identified three disease states where we believe FPC may have the biggest impact.~~

~~Dialysis~~Concentrates Business: ~~We are~~Rockwell is the second largest supplier ~~and one~~ of ~~the two major suppliers of~~life-sustaining hemodialysis ~~concentrates~~concentrate products to dialysis clinics in the United States. ~~We manufacture, sell and deliver hemodialysis concentrates, which~~Our concentrate products are used to ~~maintain human life~~sustain patient lives by removing toxins and balancing electrolytes in ~~the~~a dialysis patient’s bloodstream. A key element of our dialysis business strategy going forward is to improve the strength of our concentrates business. We ~~have core capabilities in~~believe that we can achieve this by creating efficiencies, enhancing our manufacturing ~~hemodialysis~~and transportation operations, and fully recouping manufacturing and shipping expenses to drive profitability.

To date, our concentrates ~~in three facilities, totaling 159,000 square feet, located in Michigan, Texas~~business has operated at a loss. This loss has accelerated due to inflation, which has increased our manufacturing and ~~South Carolina.~~operating costs. We ~~also have core capabilities~~undertook discussions with our largest customers to renegotiate our existing supply contracts to improve the profitability of this business line. On April 6, 2022, we amended our agreement with our long-time partner, DaVita, Inc. ("DaVita"), a leading provider of kidney care, to enable us to stabilize our concentrates business. The amended agreement provides a stronger financial arrangement which encompasses pricing, cost share, cost cutting, and joint efforts to improve supply chain, all of which is intended to drive Rockwell’s concentrates business to operate profitably in the ~~logistics~~future. In addition to the amended agreement, DaVita invested $15 million in preferred stock in two equal tranches. The first tranche of ~~delivering these products~~$7.5 million was funded on April 7, 2022. The second tranche of $7.5 million was funded on June 16, 2022. We are reviewing our entire supply chain to ~~dialysis clinics throughout most of~~identify opportunities for improvement, prioritizing initiatives that will have the ~~United States.~~largest impact on long-term efficiency, profitability, and growth.

TRIFERIC®: Our first two branded products from our FPC platform, ~~Triferic®~~TRIFERIC® (dialysate) and ~~Triferic AVNU® (IV)~~TRIFERIC® AVNU (intravenous, “IV”), are used to maintain hemoglobin in patients undergoing hemodialysis. We ~~are building on our reputation and industry presence by commercializing then to medium and small dialysis organizations. We~~ began commercializing ~~Triferic~~TRIFERIC® and ~~Triferic~~TRIFERIC® AVNU in the United States in the second half of 2019 and in early 2021, respectively. In April 2021, we received marketing approval for ~~Triferic~~TRIFERIC® AVNU from Health Canada for the replacement of iron to maintain hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease, which is the first international regulatory approval for our intravenous therapy. ~~We expect Triferic AVNU~~In 2021, due to ~~become commercially available in Canada during 2022. Our~~restrictions from the Covid pandemic and following our assessment of our strategic priorities and development strategy, we scaled back our commercial organization and began seeking a commercial partner for ~~increasing Triferic adoption is to continue to generate data in clinics showing~~ the benefits of Triferic in real world protocols. In addition, we expect to study Triferic use with the innovations that we believe have the potential to change future medical practices (e.g. introduction and adoption of HIF-PHIs), subject to FDA approval. We believe that positive data from these studies would better position Triferic for long-term growth.United States market. We are ~~developing strategic alliance partners~~also seeking to partner with established local and regional pharmaceutical companies for ~~development,~~ regulatory approval and commercialization ~~of Triferic~~in markets outside of the United States.

~~Home Infusion Program:~~ We plan to initiate a clinical trial program of FPC for the treatment of iron deficiency anemia in the home-infusion setting. Many patient groups requiring home infusion therapies suffer from chronic diseases that

are associated with a high incidence of iron deficiency and anemia. Home infusion represents a large and rapidly-growing segment of healthcare where we believe FPC may have distinct advantages over currently available iron replacement therapy options.

~~Pipeline Development:~~ We are investigating the use of our FPC platform for the treatment of iron deficiency in hospitalized patients with acute heart failure. We believe that FPC may deliver rapidly bioavailable iron to the heart and improve cardiac energetics. This effect could help patients recover faster, resulting in shorter hospital stays and fewer 30-day re-admissions, which would be a meaningful reduction healthcare costs and human suffering.

Our ~~Growth Strategy~~

~~We plan to accelerate our~~strategy for growth ~~by combining~~includes the ~~solid foundation, strength and reputation~~expansion of our dialysis business with the high-growth potential from therapeutics derived (or generated) from our FPC platform in multiple disease states where patients can benefit the most from an effective treatment for iron deficiency. In parallel with continually seeking to drive incremental growth and efficiencies in our dialysis business unit, our strategy is to accelerate the growth of our business in large, higher-margin markets by creating and developing pharmaceutical products based on our proprietary FPC technology that address iron deficiency in patients who are currently under-treated.

~~Dialysis Business~~

We are one of the two major suppliers of hemodialysis concentrates in the United States. Over the past 25 years we have developed a core expertise in manufacturing and delivering hemodialysis concentrates. Because these concentrates are used to maintain human life by removing toxins and balancing electrolytes in the dialysis patient’s bloodstream, we manufacture them under cGMP regulations as described below. Our concentrates are manufactured in three facilities, totaling 159,000 square feet, located in Michigan, Texas and South Carolina, from which we deliver these products to dialysis clinics throughout most of the United States. We utilize our own delivery fleet as well as third parties. We employ approximately 300 people in the concentrates unit of our dialysis business.

The “Rockwell Medical” name has earned a reputation for dependability, quality and service within our customer base. This reputation was further strengthened during the recent challenges presented, not only by the COVID-19 pandemic, but also by the multitude of recent natural disasters where our team has been challenged by hurricanes, flooding and freezing, while still meeting production demands.

Our dialysis business in concentrates and our growth opportunities with FPC technology are synergistic. We are leveraging our leadership position in the dialysis sector to commercialize our first two FPC-based products, Triferic and Triferic AVNU, which are indicated for the replacement of iron to maintain hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease. We commercialize the Triferic products ourselves inTRIFERIC® sales outside the United States by licensing it to key partners for development and/or commercialization. Partnering in these regions allows us to better leverage the development, regulatory, commercial presence and ~~are partnering with established local pharmaceutical companies for~~expertise of business partners to increase sales of our products throughout the ~~regulatory approval and commercialization outside of the United States.~~

~~Although~~world. To date, we have ~~an excellent reputation for dependability~~established partnerships in China, India, Korea, Turkey, Peru and service within the dialysis sector, with concentrates and Triferic, our growth opportunities for both in the United States dialysis market are challenged by the consolidated ownership of dialysis clinics, a capitated reimbursement model and the demographics of the patient population. The two largest dialysis organizations treat approximately 73% of the patients in the United States. One manufactures its own concentrates and IV iron and we already supply concentrates to the other. Through our partnership with Baxter International, we currently supply concentrates to a significant percentage of the small and medium sized dialysis organizations. In a sector, such as kidney dialysis, with capitated reimbursement for the dialysis procedure and all included inputs, new product success depends on compelling data demonstrating improved patient outcomes and/or pharmacoeconomics versus the current standard of care in practice in the clinics. Once Medicare determined that Triferic and Triferic AVNU would be reimbursed under the fixed bundled rate, market adoption became more dependent on the generation of these data, which were not required for the drug's approval from the FDA.

~~Notwithstanding the growth limitations mentioned above, we have made progress and~~Chile. We continue to ~~be confident that Triferic has the potential to be the treatment of choice for the maintenance of hemoglobin~~pursue international licensing opportunities in ~~dialysis patients. Toward this end, we have increased our efforts in generating real world data in clinics with current protocols, which we believe will help with the adoption of Triferic~~other countries and ~~Triferic AVNU as these results are developed~~regions.

FPC Platform and ~~disseminated over time. In addition, we believe the hemodialysis industry may experience a great deal of change over the next several years. We plan to take the steps necessary to~~

Home Infusion:

generate the data necessary to potentially allow Triferic and Triferic AVNU to benefit from these new innovations, such as the potential approval of a class of drugs, known as hypoxia-inducible factor prolyl hydroxylase inhibitors ("HIF-PHIs"), as well as the new, solid-state dialysis equipment in development. We are planning to study Triferic in combination with these potential new innovations as they become available.

~~A key element of our dialysis business~~ Our strategy is to also improve the strength of our concentrates business by creating efficiencies and enhancing our manufacturing and transportation operations. We have launched projects to identify ways to improve the overall profitability of these core operations. Specifically, we are reviewing our entire supply chain to identify opportunities for improvement, prioritizing initiatives that will have the largest impact on long-term efficiency, profitability and growth.

~~Home Infusion~~

~~Our growth strategy~~going forward is to go beyond our foundational business in dialysis by leveraging the pre-clinical ~~clinical pharmacology~~ and ~~safety~~clinical data from ~~Triferic.~~the development of TRIFERIC® in new therapeutic settings such as home infusion. We ~~are planning to develop an FPC-based therapeutic for iron deficiency to be given in~~believe the home infusion ~~setting. According~~setting represents a natural pathway to expand our FPC platform as many of the ~~National Home Infusion Association,~~patients suffer from chronic diseases associated with the development of iron deficiency and anemia.

The number of patients served by home infusion therapy ~~has grown~~grew from approximately 800,000 in 2010 to over 3,000,000 in ~~2019. The home infusion setting~~2019 and is ~~expected~~projected to ~~continue to expand, which has been further accelerated by~~accelerate in the ~~COVID-19 pandemic and the desire to reduce or eliminate hospital and or clinic exposure.~~wake of COVID-19. Many patient groups requiring home infusion therapies suffer from diseases that are associated with an incidence of iron deficiency and anemia. For example, it is estimated ~~that~~ 40% to 55% of

all home parenteral nutrition patients are iron ~~deficient. We~~deficient at any time. Based on pre-clinical data and clinical data in other therapeutic settings, we believe ~~based on our data with hemodialysis patients,~~ FPC ~~as a home infusion therapy for iron deficiency anemia~~ may have distinct advantages over currently available iron replacement therapy ~~options.~~options in the home infusion setting.

~~We plan~~In late 2021, we filed an Investigational New Drug (“IND”) application with the United States Food and Drug Administration (“FDA”) for the treatment of iron deficiency anemia in patients, who are receiving medications in the home infusion setting. Based on ~~initiating~~feedback received from the FDA, and subject to having sufficient working capital resources, we have made plans to launch a Phase 2II clinical ~~study~~trial in ~~home infusion patients with iron deficient anemia during~~ the ~~second~~first half of ~~2021~~2023 to confirm the dose and duration of FPC treatment. We would expect to have top-line data from the trial inapproximately 12 to 18 months following commencement of the ~~second half~~trial. In the interim, we continue to assess our strategic priorities and rationalizing our development strategy based on risk profiles of 2022. Prior to commencing this study, the company is planning to further review and discuss this clinical plan with the FDA. After reviewing the development plan with the FDA, and subject to clarifying expected clinical development requirements, we expect to initiate the trial in the second half of 2021.each opportunity.

Pipeline ~~Development~~

Development:In our ~~R&D~~research and development pipeline, ~~we are also~~Rockwell is exploring FPC’s impact inon the treatment of ~~iron deficiency in~~ hospitalized acute heart failure ~~patients. More~~patients, which affects more than one million people in the United States ~~are hospitalized each year for acute heart failure.~~annually Clinical improvement in heart failure has already been demonstrated in an outpatient [chronic] setting with ~~older first-generation~~large macromolecular forms of ~~IV iron in clinical trials in the outpatient setting.~~intravenous iron. We believe ~~that~~ FPC may ~~deliver~~improve cardiac energetics during hospitalization by delivering rapidly bioavailable iron to the ~~heart and improve cardiac energetics during hospitalization.~~heart. This effect could help patients recover faster potentially resulting in ~~improved function,~~ shorter hospital stays and fewer 30-day re-admissions. If ~~so,~~realized, these outcomes ~~would~~could translate into a meaningful reduction in healthcare costs and human suffering. ~~We expect to communicate with the FDA in 2021 regarding a development pathway for this indication.~~

We continue exploring other potential patient populations for application of our technology. We are considering disease states where patients can benefit the most from an effective treatment for iron deficiency, and where the development path, cost estimates and reimbursement are the most favorable.

Reverse Stock Split

On May 9, 2022, the stockholders of the Company authorized our Board of Directors to effect a reverse stock split of all outstanding shares of common stock, warrants and options. The Board of Directors subsequently approved the implementation of a reverse stock split as a ratio of one-for-eleven shares, which became effective on May 13, 2022. The Company’s outstanding stock options were also adjusted to reflect the one-for-eleven reverse stock split of the Company’s common stock. Outstanding stock options were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased. The reverse stock split resulted in an adjustment to the Series X convertible preferred stock conversion prices to reflect a proportional decrease in the number of shares of common stock to be issued upon conversion. All share and per share data in these condensed consolidated financial statements and related notes hereto have been retroactively adjusted to the account for the effect of the reverse stock split for the three- and six-month periods ended June 30, 2022 and 2021, respectively, and the balance sheet at June 30, 2022 and December 31, 2021.

Results of Operations for the Three Months Ended June 30, ~~2021~~2022 and ~~2020~~2021

The following table summarizes our operating results for the periods presented below (dollars in thousands):


		For the Three Months Ended June 30,											For the Three Months Ended June 30,
		2021		% of Revenue		2020		% of Revenue		% Change			2022		% of Revenue		2021		% of Revenue		% Change

Net Sales	Net Sales	$	15,137			$	15,896			(4.8)	%	Net Sales	$	18,682			$	15,137			23.4	%
Cost of Sales	Cost of Sales	15,399		101.7	%	15,015		94.5	%	2.6		Cost of Sales	16,937		90.7	%	15,399		101.7	%	10.0
Gross (Loss) Profit	Gross (Loss) Profit	(262)		(1.7)		881		5.5		(129.7)		Gross (Loss) Profit	1,745		9.3		(262)		(1.7)		(766.0)

Research and Product Development	Research and Product Development	2,416		16.0		1,616		10.2		49.5		Research and Product Development	926		5.0		2,416		16.0		(61.7)
Selling and Marketing	Selling and Marketing	1,468		9.7		1,997		12.6		(26.5)		Selling and Marketing	526		2.8		1,468		9.7		(64.2)
General and Administrative	General and Administrative	3,677		24.3		2,871		18.1		28.1		General and Administrative	4,775		25.6		3,677		24.3		29.9

Operating Loss	Operating Loss	$	(7,823)	(51.7)	%	$	(5,603)	(35.2)	%	39.6	%	Operating Loss	$	(4,482)	(24.0)	%	$	(7,823)	(51.7)	%	(42.7)	%

Net Sales

During the three months ended June 30, ~~2021,~~2022, our net sales were ~~$15.1~~$18.7 million compared to net sales of ~~$15.9~~$15.1 million during the three months ended June 30, ~~2020.~~2021. The ~~decrease~~increase of ~~$0.8~~$3.5 million was primarily due to ~~a decrease in sales~~the restructuring of ~~dialysis concentrates products.~~our supply contract with DaVita and increased pricing to other customers.

Gross Profit (Loss)

Cost of sales during the three months ended June 30, ~~2021~~2022 was $16.9 million, resulting in gross profit of $1.7 million during the three months ended June 30, 2022, compared to cost of sales of $15.4 million ~~resulting in~~and a gross loss of $0.3 million during the three months ended June 30, ~~2021, compared to cost of sales of a $15.0 million and a gross profit of $0.9 million during the three months ended June 30, 2020.~~2021. Gross profit ~~decreased~~increased by ~~$1.2~~$2.0 million ~~mainly~~primarily due to the restructuring of our supply contract with DaVita, a ~~decrease~~slight reduction of transportation costs due to efficiency initiatives being implemented and increased pricing to other customers. As a result, the Company expects an improvement in ~~concentrate sales and an increase in costs related to protocols implemented because~~margins for the remainder of ~~the ongoing COVID-19 pandemic, shipping, fuel and labor.~~2022.

Research and Product Development Expense

Research and product development expenses were $0.9 million and $2.4 million for the three months ended June 30, 2022 and 2021, ~~compared with $1.6~~respectively. Research and product development expenses decreased by $1.5 million due to the resignation of our Chief Development Officer and shifting our project timelines.

Selling and Marketing Expense

Selling and marketing expenses were $0.5 million during the three months ended June 30, ~~2020. The increase of $0.8 million was primarily due to the Company continuing to invest in its medical and scientific programs to support the continued advancement of our FPC technology platform.~~

~~Selling and Marketing Expense~~

~~Selling and marketing expenses were~~2022, compared with $1.5 million during the three months ended June 30, ~~2021, compared with $2.0 million during the three months ended June 30, 2020.~~2021. The decrease of ~~$0.5~~$0.9 million is ~~primarily~~ due to a decrease in marketing ~~costs related to Triferic (dialysate) partially offset by a slight increase in costs associated with the launch of Triferic AVNU.~~spend for our TRIFERIC® products and previous headcount reduction.

General and Administrative Expense

General and administrative expenses were $4.8 million during the three months ended June 30, 2022, compared with $3.7 million during the three months ended June 30, ~~2021, compared with $2.9~~2021. The increase of $1.1 million ~~during~~is due primarily to a one-time charge for the severance agreement for our former Chief Executive Officer and the accrual of estimated employee performance compensation.

Other Income (Expense)

Other income for the three months ended June 30, ~~2020. The increase of $0.8 million is due primarily to an increase in stock compensation of $1.9 million, which~~2022 was a decrease in incentive compensation in Q2 2020 of $1.5 million from forfeited equity awards of the former President and Chief Executive Officer; partially offset by a decrease of $0.8 million for the reduction of severance costs related to our former President and Chief Executive Officer.

~~Other Income (Expense)~~

negligible. Other income for the three months ended June 30, 2021 was $7,000, consisting primarily of interest income. Other ~~income~~expense for the three months ended June 30, ~~2020~~2022 was ~~$0.1~~$0.5 million ~~consisting primarily~~ of interest ~~income.~~expense related to our debt facility (see Note 14 to the condensed consolidated financial statements included elsewhere in this Form 10-Q for more information on our debt facility). Other expense for the three months ended June 30, 2021 was $0.6 million of interest expense related to our debt ~~facility (see Note 15 for more~~facility.

2823

information on our debt facility). Other expense for the three months ended June 30, 2020 was $1.4 million, consisting of interest expense of $0.5 million related to our debt facility and warrant modification expense of $0.8 million.

Results of Operations for the Six Months Ended June 30, ~~2021~~2022 and ~~2020~~2021

The following table summarizes our operating results for the periods presented below (dollars in thousands):


		For the Six Months Ended June 30,											For the Six Months Ended June 30,
		2021		% of Revenue		2020		% of Revenue		% Change			2022		% of Revenue		2021		% of Revenue		% Change

Net Sales	Net Sales	$	30,611			$	31,753			(3.6)	%	Net Sales	$	34,806			$	30,611			13.7	%
Cost of Sales	Cost of Sales	30,471		99.5	%	29,759		93.7	%	2.4		Cost of Sales	33,846		97.2	%	30,471		99.5	%	11.1
Gross Profit	Gross Profit	140		0.5		1,994		6.3		(93.0)		Gross Profit	960		2.8		140		0.5		585.7

Research and Product Development	Research and Product Development	4,224		13.8		3,438		10.8		22.9		Research and Product Development	2,494		7.2		4,224		13.8		(41.0)
Selling and Marketing	Selling and Marketing	3,319		10.8		4,069		12.8		(18.4)		Selling and Marketing	981		2.8		3,319		10.8		(70.4)
General and Administrative	General and Administrative	7,602		24.8		8,145		25.7		(6.7)		General and Administrative	8,592		24.7		7,602		24.8		13.0

Operating Loss	Operating Loss	$	(15,005)	(49.0)	%	$	(13,658)	(43.0)	%	9.9	%	Operating Loss	$	(11,107)	(31.9)	%	$	(15,005)	(49.0)	%	(26.0)	%

Net Sales

During the six months ended June 30, ~~2021,~~2022, our net sales were ~~$30.6~~$34.8 million compared to net sales of ~~$31.8~~$30.6 million during the six months ended June 30, ~~2020.~~2021. The ~~decrease~~increase of ~~$1.2~~$4.2 million ~~was~~was primarily due to ~~a decrease in sales~~the restructuring of ~~dialysis concentrates products.~~our supply contract with DaVita and increased pricing to other customers.

Gross Profit

Cost of sales during the six months ended June 30, ~~2021~~2022 was $33.8 million, resulting in gross profit of $1.0 million during the six months ended June 30, 2022, compared to cost of sales of a $30.5 million ~~resulting in~~and a gross profit of $0.1 million during the six months ended June 30, ~~2021,~~2021. Gross profit increased by $0.8 million primarily due to the restructuring of our supply contract with DaVita, a slight reduction of transportation costs due to efficiency initiatives being implemented and increased pricing to other customers.

Research and Product Development Expense

Research and product development expenses were $2.5 million for the six months ended June 30, 2022, compared ~~to cost of sales of a $29.8 million and a gross profit of $2.0~~with $4.2 million during the six months ended June 30, ~~2020. Gross profit decreased by $1.9~~2021. This decrease of $1.7 million ~~mainly~~ is primarily due to ~~a decrease in concentrate sales~~the resignation of our Chief Development Officer and ~~an increase in costs related to protocols implemented because of the ongoing COVID-19 pandemic, shipping~~shifting our project timelines.

Selling and ~~fuel costs~~Marketing Expense

Selling and ~~labor.~~

~~Research and Product Development Expense~~

~~Research and product development~~marketing expenses were ~~$4.2 million for the six months ended June 30, 2021, compared with $3.4~~$1.0 million during the six months ended June 30, 2020. This increase of $0.8 million is primarily due to continued investments the Company is making in its medical and scientific programs to support the continued advancement of our FPC technology platform.

~~Selling and Marketing Expense~~

~~Selling and marketing expenses were~~2022, compared with $3.3 million during the six months ended June 30, ~~2021, compared with $4.1~~2021. The decrease of $2.3 million is primarily due to a decrease in marketing spend for our TRIFERIC® products and previous headcount reductions.

General and Administrative Expense

General and administrative expenses were $8.6 million during the six months ended June 30, ~~2020. The decrease of $0.8 million is primarily due to a decrease in marketing costs related to Triferic (dialysate) partially offset by a slight increase in costs associated~~2022, compared with ~~the launch of Triferic AVNU.~~

~~General and Administrative Expense~~

~~General and administrative expenses were~~ $7.6 million during the six months ended June 30, ~~2021, compared with $8.1~~2021. The increase of $1.0 million ~~during~~is due primarily to a one-time charge related to the severance agreement for our former Chief Executive Officer and the accrual of estimated employee performance compensation.

Other Income (Expense)

Other income for the six months ended June 30, ~~2020. The decrease~~2022 was $4,000, consisting primarily of $0.5 million is due primarily to a decrease of $0.8 million from the completion of severance pay related to our former President and Chief Executive Officer (CEO); a decrease in legal costs of $0.3 million, relating to previous litigation that has since been resolved; and a decrease in insurance and accounting costs of $0.2 million, relating to reduced premiums; partially offset by an increase of $0.7 million for stock compensation, relating to a decrease in Q2 2020 incentive compensation from forfeited equity awards related to our former President and CEO.

~~Other Income (Expense)~~

interest income. Other income for the six months ended June 30, 2021 was $18,000, consisting primarily of interest income. Other ~~income~~expense for the six months ended June 30, ~~2020~~2022 was ~~$0.2~~$1.0 million ~~consisting primarily~~ of interest ~~income.~~expense related to our debt facility (see Note 14 for more information on our debt facility). Other expense for the six months ended June 30, 2021 was $1.2 million of interest expense related to our debt facility (see Note 15 for more information on our debt facility). Other expense for the six months ended June 30, 2020 was $1.5 million, consisting of warrant modification expense of $0.8 million and interest expense of $0.6 million related to our debt facility.

3024

Liquidity and Capital Resources

Since inception, Rockwell has incurred significant net losses and has funded its operations primarily through revenue from commercial products, proceeds from the issuance of debt and equity securities and payments from partnerships. At June 30, 2021, Rockwell had an accumulated deficit of approximately $353.6 million and stockholders' equity of $18.2 million. As of June 30, ~~2021, Rockwell~~2022, we had approximately ~~$41.0~~$30.8 million of cash and cash equivalents, ~~and investments available-for-sale,~~ and working capital of ~~$18.4~~$28.7 million. Net cash used in operating activities for the six months ended June 30, ~~2021~~2022 was approximately ~~$17.4~~$15.7 million.

On April 6, 2022, the Company and DaVita entered into an amendment (the "Amendment") to the Products Purchase Agreement, dated July 1, 2019, under which the Company supplies DaVita with certain dialysis concentrates. Under the Amendment, the Company and DaVita agreed to certain price increases, effective May 1, 2022, as well as the pass-through of certain inflationary costs, determined on a quarterly basis. The Amendment also requires the Company to implement certain cost containment and cost-cutting measures. The Amendment contains certain covenants with respect to the Company’s ongoing operations, including a minimum cash covenant of $10 million, or we will be in default under the Products Purchase Agreement. An event of default could result in termination of that agreement.

On April 6, 2022, the Company and DaVita entered into a Securities Purchase Agreement (the “SPA”), pursuant to which the Company issued $15 million of preferred stock to DaVita in two separate tranches. The Company initially issued 7,500 shares of a newly designated series of preferred stock, which is ~~subject~~designated “Series X Convertible Preferred Stock” (the “Series X Preferred Stock”) for gross proceeds of $7.5 million. On June 15, 2022, the Company issued to DaVita an additional 7,500 shares of Series X Preferred Stock in a second closing (the “Second Tranche”) for an additional $7.5 million. The Second Tranche was conditioned upon the Company raising an additional $15 million in capital within a certain ~~covenants~~timeline, which took place on June 2, 2022.

On April 8, 2022, the Company entered into a sales agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), pursuant to which the Company may offer and ~~cure provisions~~sell from time to time up to $12,200,000 of shares of Company’s common stock through the Agent. The offering and sale of such shares has been registered under ~~its Loan Agreement~~the Securities Act of 1933, as amended (the “Securities Act”), pursuant to the Company’s Registration Statement on Form S-3 (File No. 333-259923) (the “Registration Statement”), which was originally filed with ~~Innovatus.~~the Securities and Exchange Commission (“SEC”) on September 30, 2021 and declared effective by the SEC on October 8, 2021, the base prospectus contained within the Registration Statement, and a prospectus supplement that was filed with the SEC on April 8, 2022. As of June 30, 2022, the ~~date~~Company sold 7,500 shares of ~~this report,~~its common stock pursuant to the Sales Agreement for gross proceeds of $15,135, at a weighted average selling price of approximately $2.02. The Company paid $378 in commissions and offering fees. Approximately $12.2 million remains available for sale under the ATM facility. Under the RD Purchase Agreement and the PIPE Purchase Agreement discussed below, the Company has agreed not to make any sales under any at-the-market offering facility, including pursuant to the Sales Agreement, until at least January 1, 2023 (or until such later time when the Company is ~~in compliance with all covenants. As a result of the ongoing COVID-19 pandemic and its effect on the Company's~~permitted to make additional sales ~~activities, among other factors,~~under Instruction I.B.6 to Form S-3).

On May 30, 2022, the Company ~~may not be able~~entered into a Securities Purchase Agreement (the “RD Purchase Agreement”) with the purchaser named therein (the “Purchaser”), pursuant to ~~satisfy such covenants over the next 12 months. However, based on the foregoing,~~which the Company ~~has classified amounts payable under~~agreed to issue and sell, in a registered direct offering (the “Offering”), 844,613 shares of its common stock at price of $1.39 per share, and prefunded warrants to purchase up to an aggregate of 7,788,480 shares of common stock (the “Pre-Funded Warrants” and the ~~Loan Agreement as~~shares of common stock underlying the Pre-Funded Warrants, the “Warrant Shares”). The purchase price of each Pre-Funded Warrant was equal to the price at which a ~~current liability. If~~share of common stock was sold to the public in the Offering, minus $0.0001, and ~~when~~the exercise price of each Pre-Funded Warrant is $0.0001 per share.

Also on May 30, 2022, concurrently with the Offering, the Company ~~reaches an agreement with Innovatus to avoid an event of default, the amounts payable under the Loan~~entered into a Securities Purchase Agreement ~~will be reclassified. The financial statements for June 30, 2021, have been prepared~~ with the ~~assumption that~~Purchaser (the “PIPE Purchase Agreement”) relating to the offering and sale (the “Private Placement”) of warrants to purchase up to a total of 9,900,990 shares of common stock and pre-funded warrants to purchase up to a total of 1,267,897 shares of common stock (the “PIPE Warrants”). Each warrant was sold at a price of $0.125 per underlying warrant share and is exercisable at an exercise price of $1.39 per share. The purchase price of each Pre-Funded Warrant was equal to the price at which a share of common stock was sold to the public in the Offering, minus $0.0001, and the exercise price of each prefunded warrant is $0.0001 per share. The Offering and the Private Placement closed on June 2, 2022. The net proceeds to the Company ~~will be able~~from the Offering and the Private Placement were approximately $14.9 million, after deducting fees and expenses.

The Offering and the Private Placement closed on June 2, 2022. The net proceeds to ~~agree to an appropriate remedy during the applicable cure period for any future breaches of operating covenants. If~~ the Company ~~is unable to comply with~~from the ~~covenants under~~Offering and the ~~Loan Agreement, it would pursue all available cure options in order to regain compliance (See Note 15 for further detail).~~

~~The Company expects it will require additional capital to sustain its operations~~Private Placement were approximately $14.9 million, after deducting fees and make the investments it needs to execute its strategic plan, including the commercialization of Triferic (dialysate) and Triferic AVNU in dialysis, generating additional data for Triferic in dialysis, developing FPC for iron deficiency anemia in patients undergoing home infusion and for progressing our pipeline development program of new indications for its FPC platform. If the Company is unable to generate sufficient revenue from sales of its commercial products and from partnerships, the Company will need to obtain additional equity or debt financing. If the Company attempts to obtain additional debt or equity financing, the Company cannot assume that such financing will be available on favorable terms, if at all.

expenses.

Based on the currently available working capital, and ~~managements assumption that the Company will be able to agree to an appropriate remedy,~~capital raises described above, management believes the Company currently has sufficient funds to meet its operating requirements for at least the next twelve months from the date of the filing of this report.

The Company expects it will require additional capital to sustain its operations and make the investments it needs to execute its strategic plan in developing FPC for iron deficiency anemia in patients undergoing home infusion therapy and for progressing our pipeline development program of new indications for our FPC platform. If the Company attempts to obtain additional debt or equity financing, the Company cannot assume such financing will be available on favorable terms, if at all.

In addition, the Company is subject to certain covenants and cure provisions under our Loan Agreement with Innovatus. As of the date of this report, the Company is in compliance with all covenants (See Note 14 to the condensed consolidated financial statements included elsewhere in this Form 10-Q for more information on our debt facility).

The COVID-19 pandemic and resulting domestic and global disruptions, particularly in the supply chain and labor market, among other areas, have adversely affected our business and operations, including, but not limited to, our sales and marketing efforts and our research and development activities, our plant and transportation operations and the operations of third parties upon whom we rely. The Company's international business development activities may also continue to be negatively impacted by COVID-19.

The COVID-19 pandemic and the resulting global disruptions and recent inflationary pressures have caused significant volatility in financial and credit markets. Rockwell has utilized a range of financing methods to fund its operations in the past; however, current conditions in the financial and credit markets may limit the availability of funding, refinancing or increase the cost of funding. Due to the rapidly evolving nature of the global situation, it is not possible to predict the extent to which these conditions could adversely affect the Company's liquidity and capital resources in the future.

General

The actual amount of cash ~~that~~ we will need to execute our business strategy is subject to many factors, including, but not limited to, the expenses and revenue associated with the commercial operations in the United States and internationally (with partners); the timing and magnitude of cash received from drug product sales; the timing and expenditures associated with the development programs including our FPC technology for home infusion and potentially acute heart failure; and the costs associated with our manufacturing and transportation operations related to our concentrate ~~business; any potential accelerated amortization under the Loan Agreement in the event of a failure to satisfy operating covenants..~~business.

We may elect to raise capital in the future through one or more of the following: (i) equity and debt raises through the equity and capital markets, though there can be no assurance ~~that~~ we will be able to secure additional capital or funding on acceptable terms, or if at all; and (ii) strategic transactions, including potential alliances and collaborations focused on markets outside the United States, as well as potential combinations (including by merger or acquisition) or other corporate transactions. In particular, our Baxter Agreement prohibits us from entering into a contract that would encumber the assets used in our concentrate business without the prior written consent of Baxter. Due to the fact that the assets used in our concentrate business currently constitute a substantial portion of the tangible assets we own other than our drug inventory, we may not be able to, or we may find it difficult, to obtain secured debt financing without the consent of Baxter.

We believe ~~that~~ our ability to fund our activities in the long term will be highly dependent upon 1) our ability to execute on the development of the FPC platform for new therapies, ~~and~~ 2) our ability to restructure our other significant commercial contract within our concentrate business, and 3) our ability to find a commercial partner to commercialize and increase adaptation of ~~Triferic~~TRIFERIC® (dialysate) and ~~Triferic~~TRIFERIC® AVNU. ~~Both~~All of these strategies isare subject to significant risks and uncertainties such that there can be no assurance ~~that~~ we will be successful is achieving approval of FPC in a new therapeutic area, we will be successful in restructuring our commercial agreements in our concentrate business or ~~that~~ we will be able to find a commercial partner and have sustained commercial success with ~~Triferic~~TRIFERIC® (dialysate) and ~~Triferic~~TRIFERIC® AVNU. If our planned clinical program is delayed or fails, if our other significant commercial contract in the concentrate business cannot be restructured in a way that is beneficial to Rockwell or if our ~~commercialization of Triferic~~ability to find a commercial partner for TRIFERIC® (dialysate) and/or ~~Triferic~~TRIFERIC® AVNU ~~should fail to increase sales,~~fails, we may be forced to implement cost-saving measures that may potentially have a negative impact on our activities and potentially the results of our research and development programs. Even though we began commercialization of Triferic (dialysate) and Triferic AVNU as planned, if the results are unsuccessful, we may be unable to secure the additional capital that we will require to continue our

~~research and development activities and operations, which could have a material adverse effect on our business.~~ If we are unable to raise the required capital, we may be forced to curtail all of our activities and, ultimately, cease operations. Even if we are able to raise sufficient capital, such financings may only be available on unattractive terms, or result in significant dilution of stockholders’ interests and, in such event, the market price of our common stock may decline.

Cash Used in Operating Activities

Net cash used in operating activities was $15.7 million for the six months ended June 30, 2022 compared to net cash used in operating activities of $17.4 million for the six months ended June 30, ~~2021 compared to net cash used in operating activities of $16.2 million for the six months ended June 30, 2020.~~2021. The ~~increase~~decrease in cash used from operating

activities during the current period was primarily due to an increase in net income, offset by changes in current balance sheet accounts in the ordinary course of business of approximately ~~$3.0~~$2.0 million, including a decrease of accounts payable of $1.6 million, an increase in net ~~accounts~~account receivable of ~~$1.2~~$1.0 million and a ~~reduction~~decrease in ~~accounts payable and accrued expense~~other liabilities of ~~approximately $0.4~~$0.8 million. ~~Overall, our cash burn for the six months ended June 30, 2021 was in line with our expectations, and we continue to expect, in aggregate, 2021 cash burn to be lower than 2020 cash burn.~~

Cash Provided by Investing Activities

Net cash provided by investing activities was ~~$1.1~~$9.1 million during the six months ended June 30, ~~2021~~2022 compared to net cash ~~provided by~~used in investing activities of ~~$0.7~~$1.1 million for the six months ended June 30, ~~2020.~~2021. The net cash provided by investing activities during the six months ended June 30, ~~2021~~2022 was primarily due to sales and purchase of available-for-sale investments during the quarter. All investments available-for-sale have been liquidated as of June 30, 2022.

Cash Provided by (Used in) ~~Provided by~~ Financing Activities

Net cash ~~used in~~provided by financing activities was ~~$6,000~~$24.1 million during the six months ended June 30, ~~2021~~2022 compared to the net cash provided by financing activities of ~~$30.4 million~~nil for the six months ended June 30, ~~2020.~~2021. The net cash provided during the six months ended June 30, ~~2020~~2022 was primarily due to ~~net proceeds of $21.2 million related to proceeds from the debt facility and $8.0 million from the sale of our common stock, related to our public offering,~~multiple equity raises (See Note 10), offset by ~~$0.8 million for~~ payments on the Company's debt and short term ~~notes.~~note payable.

~~COVID-19 Impact~~Contractual Obligations and Other Commitments

The COVID-19 pandemic and resulting global disruptions have adversely affected our business and operations, including, but not limited to, our sales and marketing efforts and our research and development activities, and the operations of third parties upon whom we rely. Quarantines, shelter-in-place, executive and similar government orders may negatively impact our sales and marketing activities, particularly if our sales representatives are unable to interact with current and potential customersSee Note 12 to the ~~same extent as before onset of~~condensed consolidated financial statements included elsewhere in this Form 10-Q for additional disclosures. There have been no other material changes from the ~~COVID-19 pandemic. The Company's international business development activities may also continue~~Contractual Obligations and Other Commitments disclosed in Note 14 to ~~be negatively impacted by COVID-19, especially with~~ the ~~recent surge~~consolidated financial statements included in ~~infections internationally, ongoing international travel restrictions and quarantines or shelter-in-place orders.~~our Annual Report on Form 10-K for the year ended December 31, 2021.

The COVID-19 pandemic and resulting global disruptions have caused significant volatility in financial and credit markets. We have utilized a range of financing methods to fund our operations in the past; however, current conditions in the financial and credit markets may limit the availability of funding or increase the cost of funding. Due to the rapidly evolving nature of the global situation, it is not possible to predict the extent to which these conditions could adversely affect our liquidity and capital resources in the future.

Critical Accounting Policies and Significant Judgments and Estimates

Our critical accounting policies and significant estimates are detailed in our Annual Report on Form 10-K for the year ended December 31, ~~2020.~~2021. Our critical accounting policies and significant estimates have not changed from those previously disclosed in our Annual Report on Form 10-K for the year ended December 31, ~~2020.~~2021.

Recently issued and adopted accounting pronouncements:

We have evaluated all recently issued accounting pronouncements and believe such pronouncements do not have a material effect our financial statements. See Note 3 ofto the condensed consolidated financial statements ~~at June 30, 2021.~~

included elsewhere in this Form 10-Q.

~~ROCKWELL MEDICAL, INC. AND SUBSIDIARIES~~

~~Notes to Condensed Consolidated Financial Statements~~

~~(Unaudited)~~

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Per §229.305 of Regulation S-K, the Company, designated a Smaller Reporting Company as defined in §229.10(f)(1) of Regulation S-K, is not required to provide the disclosure required by this Item.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures ~~that are~~ designed to ensure material information required to be disclosed in our reports ~~that~~ we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and ~~that~~ such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required financial disclosure. In designing and evaluating the disclosure controls and procedures, we recognized ~~that~~ a control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance ~~that~~ the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected. Management ~~necessarily~~ was required to apply its judgment in evaluating the cost‑benefit relationship of possible controls and procedures.

Under the supervision of and with the participation of our management, including the Company’s Chief Executive Officer and Chief Financial Officer, we evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of June 30, ~~2021.~~2022. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded ~~that~~ our disclosure controls and procedures were effective as of June 30, ~~2021.~~2022.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting in connection with the evaluation required by Rule 13a-15(d) of the Exchange Act that occurred during the period covered by this Quarterly Report on Form 10-Q that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

~~The disclosure set forth above in Note 14 (Commitments and Contingencies –Litigation) to our unaudited condensed consolidated financial statements is incorporated herein by reference.~~

~~Additionally, we~~We may be involved in certain routine legal proceedings from time to time before various courts and governmental agencies. We cannot predict the final disposition of such proceedings. We regularly review legal matters and record provisions for claims ~~that are~~ considered probable of loss. The resolution of these pending proceedings is not expected to have a material effect on our operations or consolidated financial statements in the period in which they are resolved.

Item 1A. Risk Factors

Our business is subject to various risks, including those described in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2021. There have been no material changes to the risk factors set forth in our Annual Report on Form 10-K for the year ended December 31, ~~2020~~2021 under ~~“Item~~"Item 1A —- Risk ~~Factors.”~~Factors" except as noted below.

We rely on third party suppliers for raw materials and packaging components of our drug products. We may not be able to obtain the raw materials and proper components we need, or the cost of the materials or components may be higher than expected, any of which could impair our production or commercialization of drug products and have a material adverse effect on our business, results of operations and financial position.

We may not be able to obtain the raw materials or packaging components we need, or the price of such materials or components may rise significantly, for a variety of reasons, including but not limited to:

•a business interruption, including a force majeure, cyber-attack, labor strike at a supplier, a COVID-related halt or slowdown of supply of raw materials or production of components;

•global supply chain delays or disruptions;

•regulatory requirements or action by regulatory agencies or others against a supplier, including delays in receiving necessary approvals;

•failure of a supplier to comply with cGMP standards, which could result in quality or product failures, adulteration, contamination and/or recall;

•adverse financial or other strategic developments at or affecting a supplier;

•termination or disagreement over the terms and conditions of the supply contract by a supplier or our inability to comply with the minimums in such an agreement;

•unexpected demand for or shortage of raw materials or packaging components; and

•unexpected increases in our product demand.

Some of the suppliers for our raw materials or packaging components are single-source suppliers. If those suppliers were unable to supply us for any reason, including the reasons mentioned above, we could experience cost increases or supply interruptions. For example, we have had disputes with our API supplier for Triferic. In January 2022, we received an invoice for a penalty payment because we failed to meet certain minimum order requirements under our agreement with them. Any dispute that may arise could result in the termination of the supply agreement or loss of API that is stored at our supplier. We also experienced repeated batch failures as a result of quality issues at our other Triferic manufacturer and our packaging manufacturer has notified us that they will no longer supply packaging due to low volumes and our compliance requirements. Finding an alternative source can be expensive and take a substantial amount of time, especially when regulatory approval is required to qualify the supplier. If we are unable to obtain our raw materials and packaging components and are not able to establish alternative supply sources, or if the prices for such items increase substantially, our CMOs may not be able to produce the desired quantities of our drug products and our expected gross profit margins may be materially adversely affected.

Our drug and concentrate businesses are highly regulated, resulting in additional expense and risk of noncompliance that can materially and adversely affect our business, results of operations, financial position and cash flows.

Our businesses are highly regulated. The testing, manufacture, sale and delivery of the products we manufacture directly or through third party CMOs are subject to extensive regulation by the FDA and by other federal, state and foreign authorities, including, with respect to our transportation operations, the U.S. Department of Transportation. Before drug product candidates or medical devices, such as our concentrate products, can be commercially marketed in the United States, the FDA must give either premarket approval or 510(k) clearance. After a product is approved, regulatory authorities may impose significant restrictions on a product’s indicated uses or marketing or requirements for potentially costly post-marketing studies. Our drug products are subject to ongoing regulatory requirements for labeling, packaging, storage, advertising, promotion, sampling, record- keeping and reporting of safety and other post-market information. In addition, manufacturers and their facilities are required to comply with extensive FDA requirements, including ensuring that quality control and manufacturing procedures conform to current cGMP and applicable state laws. As such, we and our CMOs are subject to continual review and periodic inspections to assess compliance with cGMP and state laws. For example, the FDA recently conducted a routine GMP inspection of one of our manufacturing facilities and issued Form FDA-483 report with four observations,for which the inspector classified Voluntary Action Indicated. The Company expects to submit a voluntary corrective action plan by August 24, 2022. While none of the findings were serious, management time and effort will be necessary for the correction and the FDA may not be satisfied with our response. Accordingly, we and our partners must continue to expend time, money and effort in all areas to achieve and maintain regulatory compliance. We are also required to report certain adverse reactions and production problems, if any, to applicable regulatory authorities and to comply with requirements concerning advertising and promotion for our drug products or product candidates.

If non-compliant inventory is sold or if a regulatory agency determines that we are not compliant with any applicable regulatory requirements, we may be subject to warnings from, or enforcement action by, state and federal government authorities, which may include penalties, fines, injunctions, recall or seizure of products, suspension of production, denial of future regulatory approvals, withdrawal or suspension of existing regulatory approvals, operating restrictions, injunctions and criminal prosecution. If regulatory sanctions are applied, the value of our Company and our operating results could be materially and adversely affected. For example, such actions could cause our customers to doubt the safety or efficacy of our products, which could adversely impact our business. Even a voluntary Class III recall, which is a recall of products for a defect that is unlikely to result in adverse health consequences, can have an adverse impact on the Company due to the costs of the recall or the reactions of customers. We recently conducted a Class III recall in our concentrates business due to the degradation of secondary seals on some of our bottles of concentrates, which consumed management time and effort. Our business could also be adversely affected by delays in obtaining necessary regulatory approvals and any restrictions placed by the FDA on our intended marketing or the use of our drug products.

Our failure to comply with applicable regulations could also result in product liability litigation against us. In addition, our failure to comply with applicable regulations with respect to our concentrate products could constitute a breach by us of the Distribution Agreement, providing Baxter with various remedies that would be material and adverse to us. Moreover, changes in applicable regulatory requirements could significantly increase the costs of our operations, which, if such higher costs result in price increases that exceed the thresholds specified in the Distribution Agreement, could give Baxter the right to terminate the Distribution Agreement.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None.

Item 3. Defaults Upon Senior Securities.

~~ROCKWELL MEDICAL, INC. AND SUBSIDIARIES~~

~~Notes to Condensed Consolidated Financial Statements~~

~~(Unaudited)~~

None.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

~~None.~~On August 12, 2022, the Board of Directors (the “Board”) of the Company completed a process to reclassify the membership of the Board’s three director classes in order to achieve a more equal apportionment of membership among the three director classes in accordance with the Company’s Certificate of Incorporation, as amended. Accordingly, effective August 12, 2022, John G. Cooper, a member of the Board, resigned from his position as a Class II Director (with a term expiring at the Company’s 2023 Annual Meeting of Stockholders). The Board accepted Mr. Cooper’s resignation and immediately reappointed him as a Class I Director with a term expiring at the Company’s 2025 Annual Meeting of Stockholders. Mr. Cooper will be nominated for election as Class I Director with a term expiring at the Company’s 2025 Annual Meeting of Stockholders. The resignation and reappointment of Mr. Cooper was effected for the purpose of achieving a more equal apportionment of membership among the Board’s three classes of directors, and for all other purposes, Mr. Cooper’s service on the Board is deemed to have continued uninterrupted.

Mr. Cooper continues to be appointed to the Compensation Committee, Audit Committee and Science and Technology Committee of the Board and there were no changes to any of Mr. Cooper’s compensation arrangements with or any compensation due to Mr. Cooper as a result of his resignation as a Class II Director and appointment as a Class I Director.

Item 6. Exhibits

The exhibits filed or furnished as part of this Quarterly Report on Form 10-Q are set forth on the Exhibit Index, which Exhibit Index is incorporated herein by reference.


EXHIBIT INDEX
Exhibit No.						Description

3.1						Certificate of Amendment to Certificate of Incorporation of Rockwell Medical, Inc. related to the Reverse Stock Split, dated May 12, 2022 (Company’s Form 8-K filed May 13, 2022).

3.2						Certificate of Designation of Preferences, Rights and Limitations of Series X Convertible Preferred Stock (Company’s Form 8-K filed April 8, 2022).

4.1						Form of Pre-Funded Warrant (Exhibit 4.1 to the Company’s Form 8-K filed on June 2, 2022).

4.2						Form of PIPE Warrant (Exhibit 4.2 to the Company’s Form 8-K filed on June 2, 2022).

4.3						Form of PIPE Pre-Funded Warrant (Exhibit 4.3 to the Company’s Form 8-K filed on June 2, 2022).

10.1*						Securities Purchase Agreement, dated April 6, 2022, by and between the Company and DaVita, Inc.(Exhibit 10.1 to the Company’s Form 10-Q filed on May 16, 2022).

10.2 *#						Amendment One to Products Purchase Agreement, dated April 6, 2022, by and between the Company and DaVita, Inc.(Exhibit 10.2 to the Company’s Form 10-Q filed on May 16, 2022).





10.3						Sales Agreement, dated April 8, 2022, between Rockwell Medical, Inc. and Cantor Fitzgerald & Co. (Exhibit 1.1 to the Company’s Form 8-K filed on April 8, 2022).

10.4						RD Securities Purchase Agreement, dated May 30, 2022, by and between the Company and the Purchaser signatory therein (Exhibit 10.1 to the Company’s Form 8-K filed on June 2, 2022).

10.5						PIPE Securities Purchase Agreement, dated May 30, 2022, by and between the Company and the Purchaser signatory therein (Exhibit 10.2 to the Company’s Form 8-K filed on June 2, 2022).

10.6						Registration Rights Agreement, dated June 2, 2022, by and between the Company and the Holder signatory thereto (Exhibit 10.3 to the Company’s Form 8-K filed on June 2, 2022).

10.7*+						Employment Agreement, dated June 21, 2022, between Rockwell Medical, Inc. and Mark Strobeck.

10.8*+						Rockwell Medical, Inc. Amended and Restated 2018 Long Term Incentive Plan.
31.1*						Certification of Chief Executive Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934

31.2*						Certification of Chief Financial Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934

32.1**						Certification pursuant to 18 U.S.C. Section 1350 and Rule 13a-14(b) of the Securities Exchange Act of 1934

101.INS*						XBRL Instance Document

101.SCH*						XBRL Taxonomy Extension Schema

101.CAL*						XBRL Taxonomy Extension Calculation Linkbase

101.DEF*						XBRL Taxonomy Extension Definition Database

101.LAB*						XBRL Taxonomy Extension Label Linkbase

101.PRE*						XBRL Taxonomy Extension Presentation Linkbase

104*						The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended ~~June 30, 2021,~~March 31, 2022, formatted in Inline XBRL (included as Exhibit 101)

*						Filed herewith
**						Furnished herewith and not deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act
+						Indicates management contract or compensatory plan.
#						Certain confidential portions of this exhibit were omitted by means of marking such portions with asterisks because the identified confidential portions (i) are not material and (ii) would be competitively harmful if publicly disclosed.

3429

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	ROCKWELL MEDICAL, INC.
	(Registrant)

Date: August ~~16, 2021~~15, 2022		/s/ ~~Russell Ellison~~Mark Strobeck
		~~Russell Ellison~~Mark Strobeck, Ph.D. Chief Executive Officer (Principal Executive Officer)


Date: August ~~16, 2021~~15, 2022		/s/ Russell Skibsted
		Russell Skibsted Chief Financial Officer (Principal Financial Officer)

3530


	Number of Shares	Weighted Average Exercise Price
Outstanding at January 1, 2021	750,000	$	2.20

Expired	(375,000)	2.20
Outstanding at June 30, 2021	375,000	$	2.20

Exercisable at June 30, 2021	0	$	0


	Operating		Finance
Year ending December 31, 2021 (remaining)	$	865	$	148
Year ending December 31, 2022	1,603		300
Year ending December 31, 2023	1,285		305
Year ending December 31, 2024	930		305
Year ending December 31, 2025	468		305
Remaining future payments	97		319
Total	$	5,248	$	1,682
Less present value discount	(522)		(228)
Operating and finance lease liabilities	$	4,726	$	1,454